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Resumo 
 
Atualmente, está bem documentado o duplo papel do sistema imunitário no 
desenvolvimento do cancro, que se por um lado contribuindo para a eliminação do tumor, 
por outro, pode promover a sua progressão. A tolerância imunitária é um dos processos 
descritos que permitem ao tumor escapar da resposta imunitária. Uma das principais vias 
envolvidas nesta tolerância atua através das células T reguladoras (Treg), caraterizadas 
pela expressão do factor de transcrição Forkhead box P3 (FoxP3). Estas células são uma 
subpopulação das células T CD4+ e possuem uma função imunossupressora que é 
fundamental para a manutenção da tolerância imunológica. Esta população de células é 
frequentemente observada no cancro, contribuindo para um microambiente tumoral 
imunossupressor e favorecendo a progressão tumoral. De facto, a presença de Tregs no 
infiltrado tumoral tem sido associada a um mau prognóstico da doença, apesar de não 
haver concordância entre diferentes estudos e de dados recentes sugerirem que esse 
prognóstico pode variar dependo do tipo de cancro. Apesar disto, até ao momento, ainda 
não foram elucidados os mecanismos de recrutamento e atividade das células Tregs no 
contexto tumoral. Além disso, ainda não é conhecido se as Tregs presentes no tumour são 
provenientes do timo (tTreg) ou provenientes da conversão a partir de células T CD4+ na 
periferia (pTreg).  
Assim, o objetivo desta dissertação é o de identificar a origem das Tregs presentes no 
tumor. 
Para tal, foram usados dois modelos animais de tumorigénese, os murganhos 
Lrig1CreERT2/+;Apcflox/+, que constituem um modelo de desenvolvimento de tumores 
induzíveis no intestino e colon, e murganhos FoxP3eGFP.DTR.Luci , que apresentam todas as 
Tregs marcadas com uma proteína de fluorescência verde e nos quais desenvolveram 
tumores pela inoculação subcutânea de células tumorais MC38. Após obter uma 
suspensão de células proveniente de amostras de tumor e de sangue, estas foram 
caracterizadas em termos de composição imunológica por citometria de fluxo através do 
uso dos marcadores CD3, CD4, CD25 e FoxP3. As populações de linfócitos T efectores 
CD4+ (CD3+CD4+FoxP3-) e Tregs (CD3+CD4+CD25+FoxP3+) foram isoladas e, 
posteriormente, a cadeia b do recetor das células T (TCRb) presente em cada população 
foi sequenciada pela técnica de sequenciação de nova geração (NGS). Por fim, os dados 
provenientes da sequenciação foram analisados e comparados entre as populações 
referidas anteriormente. 
A presença de Tregs no tumor foi observada em ambos os modelos animais. De seguida 
foram realizadas comparações entre o repertório de TCRb nas Tregs e nos linfócitos T 
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efectores CD4+ dos tumores, indicando que a maioria das sequências não eram partilhadas 
entre estas populações. Desta forma, é possível concluir que a maioria dos clones de Tregs 
presentes no tumores eram de origem central. Apesar disso existe uma grande quantidade 
de clones de pTregs no tumor subcutâneo vindo do ratinho FoxP3eGFP.DTR.Luci. Foi também 
efetuada uma comparação entre as populações de interesse presentes no tumor do ratinho 
Lrig1CreERT2/+;Apcflox/+ com as populações que circulavam no sangue, mostrando que alguns 
clones de Tregs periféricas são originadas no local do tumor, uma vez que apenas existe 
partilha entre as sequências de TCR das populações CD4+ T efectoras e Tregs presentes 
nas amostras do tumorais. 
Resumindo, o trabalho descrito nesta dissertação mostra que, em ambos os modelos 
animais, a maioria das clones de Tregs infiltradas no tumor parecem ter uma origem tímica 
apesar de também existir uma percentagem de Tregs convertidas na periferia e ambas 
desempenharem um papel fundamental no desenvolvimento de uma tolerância central e 
periférica, contribuindo para desvendar a sua implicação no processo de evasão 
imunológica no cancro. 
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Abstract 
 
Nowadays, it is well established that the immune system plays a dual role in cancer 
development, either by contributing to tumour elimination or by promoting its progression. 
Immunotolerance is one of the processes which may allow tumour escape from the immune 
response. One of the main players of immunotolerance are regulatory T cells (Tregs), which 
are characterized by the expression of the Forkhead box P3 (FoxP3) transcription factor. 
Tregs are a subset of CD4+ T cells with an immunosuppressive function that are 
fundamental in maintaining immunological tolerance. They are often observed in cancer, 
where they are thought to impose an immunosuppressive microenvironment that favours 
tumour progression. Indeed, the presence of tumour-infiltrating Tregs (tiTregs) is associated 
with poor prognosis, although there is some discrepant data suggesting that the prognostic 
value of tiTregs might vary according to the cancer type. Despite this, the mechanisms that 
govern the recruitment and activity of tiTregs are still poorly understood. Moreover, to date 
it has not yet been elucidated if these cells derive from thymic (central) selection of Tregs 
(tTregs), or whether tiTregs derive from the peripheral conversion of CD4+ Teffs (pTregs). 
Therefore, the aim of this dissertation is to determine the origin of tiTregs. 
We used two murine models of cancer, the Lrig1CreERT2/+;Apcflox/+ mice, which constitutes an 
inducible model of intestinal/colonic tumourigenesis, and the FoxP3eGFP.DTR.Luci mice, in 
which all Tregs are identified with a green fluorescent protein and where tumours were 
induced by subcutaneous inoculation of MC38 cells. After achieving a cell suspension from 
tumour and blood samples, immunophenotyping based on CD3, CD4, CD25 and FoxP3 
markers were performed by flow cytometry to sort CD4+ Teff cells (CD3+CD4+FoxP3-) and 
Tregs (CD3+CD4+CD25+FoxP3+) followed by T cell receptor b chain (TCRb) sequencing for 
each population by Next Generation Sequencing (NGS). Finally, the sequencing data was 
analysed and compared between the CD4+ Teff and Tregs populations. 
The presence of Tregs in the tumour site was observed in both models. Moreover, the 
comparison between the TCRb repertoire of tumour-infiltrating Tregs and CD4+ Teff cells 
indicated that the majority of TCRb sequences were not shared by these populations, 
concluding that the majority of tiTreg clones have a central origin. But in the case of MC38 
derived subcutaneous tumour there is a substantial fraction of pTregs among tiTregs. We 
also compared the TCRb sequences of CD4+ Teff and Tregs sorted from blood with the ones 
sorted from Lrig1CreERT2/+;Apcflox/+ tumour samples, and the obtained data revealed that at 
least some pTreg clones are converted from CD4+ Teff cells locally, at the tumour site. 
In summary, the work described in this dissertation shows that, in both mouse models, 
tiTreg clonotypes appear to originate mostly from the thymus but also a few pTregs 
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clonotypes were present in tumour, hinting at a role for central and peripheral tolerance in 
tumour immune escape.
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1. Introduction 
 
1.1. The immune system and cancer 
The impact of the immune system in cancer progression has been discussed by the 
scientific community for over a century [1]. In the early 20th century, Paul Ehlrich 
hypothesized that the immune system could control cancer development. However, this 
was not proven due to lack of knowledge about the composition and function of all immune 
system components, as well as insufficient experimental tools at the time [2]. Later on, some 
researchers demonstrated the stimulation of the immune system by tumour antigens and 
studies using mice showed that these can become resistant to syngeneic transplantable 
tumours induced by chemical and biological carcinogens, corroborating Paul Ehlrich’s 
hypothesis [3, 4]. These findings were the basis for the “cancer immunosurveillance” 
hypothesis. 
 
1.1.1. From cancer immunosurveillance to cancer immunoediting 
The “cancer immunosurveillance” hypothesis was officially proposed by Burnet and Thomas 
in the mid 70’s, after the discovery of the ability of antigen-presenting cells (APCs) to 
present tumour neo-antigens to immune cells and generate immune-related 
effector/memory cells [2, 5]. This theory supports the capacity of the adaptive immunity to 
prevent tumour formation, with lymphocytes having a leading role in the recognition and 
elimination of tumour cells [6].  
However, studies showed another perspective of this hypothesis when comparing 
immunocompetent to “immunodeficient” mice [1]. In a study conducted by Stutman, 
researchers used nude mice as an immunodeficient model, but these animals show the 
presence of a small amount of adaptive immune cells, such as lymphocytes, and therefore, 
were not fully immunodeficient as previously thought [1, 7]. Thus, the results observed by 
Stutman showed no significant difference between “immunodeficient” and 
immunocompetent animals in terms of spontaneous tumour incidence, including in groups 
with different characteristics, such as the age of animals or the dose of carcinogens [7, 8]. 
As a result, it was argued that these tumour cells did not express enough antigens or they 
could not trigger an immune response, not being recognized by the immune system as non-
self. Other authors defended that tumour cells are very similar to “normal cells”, inducing 
the immune system to tolerate them [1, 9]. These new experiments and opinions led to the 
fall of the immunosurveillance concept [1]. 
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In the 90s, immunodeficient animal models were improved. One of the major contributions 
to that was the discovery of the importance of interferon g (IFNg) in promoting 
immunologically induced rejection of transplanted tumour cells [1]. Another important 
contribution was the discovery of Recombination activating 2 (Rag2) gene that was found 
as an important gene in T cell receptor (TCR) and B cell receptor (BCR) rearrangement, 
being crucial for the development of T cells, natural killer T (NKT) cells and B cells [10]. 
Therefore, if the IFNg  gene or other gene involved in adaptive immunity, such as Rag2, 
were knocked out, these mice would be more susceptible to the development of 
spontaneous tumours, as well as carcinogen-induced tumours [1, 9]. According to 
Shankaran et al., tumours from different animals show different degrees of immunogenicity; 
therefore, the immune system can control tumour development but at the same time shape 
the tumour through the selection of less immunogenic clones [11]. 
Because immunosurveillance only referred the relationship between the immune system 
response and tumour elimination, a new concept emerged at this time: cancer 
immunoediting [2]. 
 
1.1.2. Cancer immunoediting 
The hypothesis of cancer immunoediting, which stresses the dual role of the immune 
system in protecting the host and promoting tumour development, was proposed by Dunn 
and Schreiber, in 2002 [9]. According to these authors, cancer immunoediting proceeds 
sequentially in three different phases: elimination, equilibrium and escape, also known as 
the three E´s (Figure 1) [12]. However, in some cases, tumour cells may directly enter into 
either the equilibrium or escape phases without passing through an earlier stage [1]. 
Nowadays, this is the most accepted theory in the scientific community regarding the tumour 
sculpting actions of the immune system.  
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Figure 1. Cancer immunoediting hypothesis. Normal cells (in grey) are transformed into tumour cells (in red) by 
the action of some carcinogens, promoting their proliferation/survival (top side). After reaching this stage, 
tumours express tumour specific markers and their growth generate a pro-inflammatory signal of recruitment of 
both innate and adaptive immune cells to the tumour site (elimination phase). These recruited cells may 
eliminate the tumour and, thus, protect the host. Still, if the elimination of the tumour is not totally complete, a 
few of the tumour cell variants may survive and enter in a new phase (equilibrium), where they may be 
maintained chronically without evidence of growth or some resistant cells could emerge by alteration of 
constitution of tumour cell variants by the immune response and go through the next stage (escape), where the 
immune system is no longer able to eliminate tumour cells and the tumour will become clinically detectable. 
Reprinted from [13]. 
 
1.1.2.1. Elimination phase 
The elimination phase is described as an updated version of the cancer immunosurveillance 
hypothesis, in which the innate and adaptive immune systems work together to detect and 
eliminate cancer cells [1, 14]. If it functions properly, the tumour is eliminated [9]. 
When tumours reach a certain size, they require an enhanced blood supply to initiate 
invasion. This growth triggers the expression of inflammatory signals, leading to the 
recruitment of innate immune cells, such as macrophages, natural killer (NK) cells and 
dendritic cells to the tumour site [12]. Some infiltrating lymphocytes like NKT cells and γδ T 
cells also recognise tumour cells and produce IFNg, which induces anti-proliferative, 
apoptotic and angiostatic effects [15]. This inflammatory process leads to the recruitment of 
more NK cells and macrophages to the tumour site, followed by the transactivation of 
macrophages and NK cells through the production of IFNg and interleukin-12 (IL-12) and 
elimination of tumour cells by secretion of tumour necrosis factor-related apoptosis-inducing 
ligand (TRAIL), perforin and reactive oxygen species (ROS) [9, 12]. 
Tumour cell fragments are then phagocytized by dendritic cells, which move to draining 
lymph nodes, where they present the antigens to CD4+ T helper cells that will produce IFNg 
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and induce the development of tumour specific CD8+ T cells [1, 9, 12]. Finally, these 
cytotoxic T lymphocytes migrate to the tumour site and destroy the remaining tumour cells, 
whose immunogenicity had been enhanced by IFNg [9]. 
 
1.1.2.2 Equilibrium phase 
Even though the immune system eliminates most tumour cells in the elimination phase, 
minor tumour cell variants may survive and progress to the next stage, the equilibrium 
phase [1]. This is usually the longest phase of the immunoediting process and can last up 
to several years [12]. In equilibrium, the immune system maintains a residual tumour cell 
pool in a functional state of dormancy, a term used to describe latent tumour cells that may 
reside in patients for decades without tumour development, but will eventually resume 
growth as either recurrent primary tumours or distant metastases [1]. This occurs due to the 
presence of lymphocytes and IFNg that continue on destroying different tumour cell clones 
[9]. More specifically, a high proportion of CD8+ T cells, NK and gd T cells, and low 
proportions of NKT cells, regulatory T cells (Treg) and myeloid-derived suppressor cells 
(MDSC), allowing the presence of residual tumour [15, 16]. Furthermore, a study by Kobel 
suggests that only adaptive immunity is responsible for maintaining the equilibrium phase, 
which contrasts with the elimination phase [17]. 
 
1.1.2.3 Escape phase 
In the last phase of the immunoediting process, the escape phase, the tumour cells that 
have acquired the ability to bypass the immune system recognition emerge as a 
progressively growing, clinically detectable tumour. This progression may occur due to 
selection by the immune system of tumour variants that are fitter to thrive and/or cancer-
induced immunosuppression [1]. Still, several scientific groups are trying to better 
understand the molecular mechanisms underlying tumour immune escape, including 
downregulation/loss of tumour antigen expression or increased resistance to cytotoxic 
immunity effects, resulting in poorly immunogenic tumour cells [1, 15]. Besides that, tumour 
cells can produce immune suppressive cytokines, such as tumour growth factor b (TGF-b), 
express negative immune checkpoints like programmed death-ligand 1 (PD-L1) or recruit 
suppressor immune cells, such as Treg cells or MDSC to promote a tumour 
microenvironment that favours the escape from the immune system [1, 14]. 
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1.2. Immunotherapy: a new approach for cancer treatment 
With growing evidence regarding the importance of the immune system in cancer 
development, a new paradigm for cancer patients treatment has emerged: cancer 
immunotherapy [18]. In this type of treatment, the focus is on the immune system rather 
than the tumour cells, which are the conventional target for traditional forms of treatment 
like chemotherapy or target therapies, such as tyrosine kinase inhibitors [19]. In this new 
approach, the treatment activates the immune system to fight cancer, mimicking what 
happens in the elimination phase of the immunoediting hypothesis. To achieve this, several 
studies focus on obtaining an effective T cell response, especially by removing the “brake” 
of CD8+ cytotoxic T cells, thereafter, eliminating the tumour. One of the new strategies to 
activate CD8+ cytotoxic T cells is the administration of immune checkpoint blockade 
molecules such as anti-PD-L1/programmed cell death-1 (PD-1) and anti-cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4) [20]. Despite the initial favourable results in the 
clinics for inhibitors of these molecules, they have only been approved for a reduced number 
of types of cancer, such as melanoma and non-small cell lung cancer, by the Food and 
Drug Administration (FDA) agency, in the USA [21]. Moreover, only a subgroup of about 
20-30% of treated patients have benefited from this treatment [22]. There are many factors 
contributing to that result: firstly, some patients had primary resistance to the treatment; 
secondly, due to dysregulation of the immune response by these immune checkpoint 
inhibitors, some patients have developed severe adverse effects and others have relapsed 
after a few months/years, despite presenting a good initial response [23]. 
For these reasons, it is important to explore and target other pathways that are not directly 
related to the activation of intrinsic CD8+ cytotoxic T cells, but through which tumour cells 
can escape from the immune response. New immunotherapeutic drugs may be used alone 
or in combination with current immunotherapy or traditional therapies, and in a wider range 
of patients that will benefit from increased overall survival [19, 24]. 
 
1.3. T cell development 
Since research of immunotherapeutic drugs is mainly focused on T cells, it is essential to 
comprehend more about T cell development. Contrary to what occurs with other immune 
cells, where all stages of development occur in the bone marrow, the primary lymphoid 
organ for T cell maturation is the thymus [25]. Besides, T cells have a unique marker, the 
TCR, which is a key element in T cell activation and is also assembled in the thymus [26]. 
Initially, T cell precursors enter the thymus and go to the cortex region. There, these cells, 
also known as thymocytes, present a double negative (DN) phenotype, since neither CD4 
or CD8 markers are expressed [27, 28]. This pool of cells includes both abT and gdT cells. 
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About 90% to 99% of T cells have the abTCR and they need two steps to form the TCR 
protein [29]. Firstly, the TCRb, also known as TRB, is rearranged and, only in cells in which 
it is assembled correctly, the TCRa is formed [27]. The TCRb gene is composed of one 
constant region (C) and three different variable regions: variable (V region), diversity (D 
region) and joining (J region), each comprising several segments (Table 1). The 
TCRa  gene is relatively similar to the TCRb  gene, despite having only two different 
variable regions, V and J [29]. 
Regarding the TCR protein, it can be divided in three parts, based on structural folds: 
complementary determining region (CDR) 1, CDR2 (encoded by the V region) and CDR3 
(encoded by the end of the V region, the entire D region and the 5´ portion of J region). Due 
to the inclusion of all the junctional diversity, CDR3 is the most diverse region, which is of 
extreme importance as it is the region that recognizes antigenic peptides [29, 30]. 
Before TCR protein assembly, it is necessary to have a recombination in the DNA strain 
regions referred. First, a couple of nucleases, Rag1 and Rag2, recognise one specific 
sequence in two random segments from different regions (V-J) and cleaves those locations. 
This sequence is present in the beginning and/or end of each segment of the V, D and J 
regions. After the DNA strains are cut, random nucleotides are added to both strains by 
terminal deoxynucleotide transferase (TdT). Finally, a complex of enzymes align both 
strains of DNA and ligate the two segments (Figure 2A) [31, 32]. In the case of the TCRb 
chain, it is necessary to recombine first the D-J and then the V -DJ regions (Figure 2B) [32]. 
Due to the random recombination in each segment of the different regions, as well as to the 
introduction of new random nucleotides by TdT enzymes, virtually every T cell will have a 
different TCR sequence. The estimated number of possible different TCR sequences is 
around 1013, which means that T cells can recognise a huge diversity of antigens, including 
self-antigens [29, 33, 34]. Despite the huge diversity of TCR sequences, we observed that 
the frequency was not similar among TCR clonotypes. Moreover, in a cancer context, the 
response to immune checkpoint inhibitors may be correlated to broad diversity and 
frequency of TCR clonotypes [35]. 
 
Table 1. Number of segments in each region of TCR-b in mouse [36]. 
TCRb Functional gene 
TRBV 22 
TRBD 2 
TRBJ 11 
TRBC 2 
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Figure 2. Schematic representation of TCRb rearrangement. (A) The Rag1/2 enzymes recognize and cleave in 
a specific sequence at the end of the segment of the V region and an initial sequence of the segment of the J 
region. After that, the TdT enzyme add some nucleotides and a complex of enzymes ligate the two segments. 
(B) Segments of D and J regions are rearranged in first followed by V-DJ rearrangement. Subsequently, a 
segment of C region joins to VDJ regions, finally forming a functional TCR. Reprinted from (A) [36]; (B) [37].  
 
 
When T cell precursors are capable of expressing the TCR on their cell surface, these cells 
acquire a double positive (DP) phenotype: CD4+CD8+ [28]. DP thymocytes are then prone 
to interact with antigens presented by MHC complexes from cortical thymic epithelial cells.  
T cell avidity will then determine the fate of thymocytes: if T cells show low avidity between 
their TCR and the antigen presented by major histocompatibility complex (MHC) class I or 
MHC class II molecules, they become CD8+ or CD4+ T cells, respectively. On the other 
hand, if T cell precursors show no avidity, they will be eliminated by neglect. This process 
is called positive selection and is followed by the migration of single positive (SP) 
thymocytes to thymus medulla. Here, SP thymocytes interact with self-peptide-MHC 
complexes presented by medullary thymic epithelial cells: low avidity interactions lead their 
exit from the thymus, while high avidity lead to elimination through negative selection [27]. 
However, this process is rather complex, as thymocytes that show an intermediate level of 
avidity to self-antigens are not eliminated by the negative selection, but give raise to Tregs, 
a special lineage of CD4+ T cells. 
Subsequently, T cells are able to differentiate into different subsets [38]. Naïve CD8+ T cells 
differentiate into cytotoxic T cells whereas naïve CD4+ T cells can differentiate into two 
groups of cells: CD4+ effector T cells (CD4+ Teff cells), such as T helper (Th)1 and Th17, 
among others and Tregs. This process of differentiation occurs by the action of specific 
cytokines, such as Il-2, Il-6 and TGF-b (Figure 3) [38, 39]. 
A B 
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Figure 3. Schematic representation of the T cell differentiation from double positive cells and the main 
extracellular signals that induce this differentiation. Adapted from [39]. 
 
1.4. Immunotolerance 
Immunotolerance is an important natural mechanism in homeostasis, as it allows the 
immune system to tolerate self-peptides and some environment peptides, preventing 
reactivity against self-cells and tissues. Deficiencies in this process often lead to allergies 
or autoimmune diseases like immune dysregulation, polyendocrinopathy, enteropathy, X-
linked (IPEX) syndrome, type 1 diabetes, autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy (APECED), among others [40, 41]. 
It can be divided in two different parts, depending on the site where T cell tolerance is 
induced: central tolerance, if arising at the site of lymphocyte development, the thymus; or 
peripheral tolerance, if arising in peripheric tissues [40]. 
This mechanism is also exploited by tumour cells to escape from the immune response and, 
thus, promote invasion and/or metastasis formation [42]. The major contribution for that to 
happen relies on the fact that malignant cells arise from the own host cells and therefore, 
most tumour cells express self-antigens to which T cells have been tolerized [43]. 
As a result, some immunotherapy approaches have focused on disrupting cancer 
immunotolerance by the adoptive transfer of immune effectors, the use of 
immunomodulatory therapy and vaccination [44] . Recently, chimeric antigen receptor 
(CAR) T cells, which are genetically modified to be reactive against tumour antigens, have 
been used in small clinical trials and FDA has already approved two CAR-T therapies [45]. 
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This shows that immunotolerance is a field with a lot of potential that may result in the 
appearance of novel approaches to treat cancer patients [44]. 
 
1.4.1. Central tolerance 
Central tolerance is acquired in the thymus by deletion of autoreactive T cells or by the 
development of Tregs [46]. The former process is collectively known as clonal deletion 
because it eliminates most of autoreactive T cells. It represents one of the main strategies 
to guarantee central tolerance [46]. The latter mechanism is known as clonal diversity, 
where a special subset of CD4+ T cells, known as Tregs, is formed. These cells recognise 
self-antigens with intermediate affinity and, thus, are not deleted by negative selection [47]. 
Therefore, they suppress possible immune responses in the periphery by certain 
autoreactive T cells that may go through negative selection without elimination [46]. 
Besides that, some reports show that some self-antigens expressed in the thymus may be 
tumour antigens that, in turn, lead to the tolerization of T cells against tumour cells in the 
context of tumour evasion [48, 49]. Additionally, peripheral dendritic cells can transport 
antigens to the thymus, where they present them to T cells, reinforcing the role of central 
tolerance which can be used by tumour to tolerate neoantigens [50-52]. 
 
1.4.2. Peripheral tolerance 
Central tolerance alone is insufficient to prevent autoimmunity or allergic diseases since not 
all antigens that are needed to tolerate T cells are expressed in the thymus, such as food 
antigens [46, 53]. Moreover, the efficacy of negative selection is not perfect and, for this 
reason, some autoreactive T cells may exit from the thymus [54]. Not surprisingly, an 
additional mechanism exists, peripheral tolerance. Through it, T cells that react against self-
antigens or some environment/ non self-antigens, in the periphery, are identified and 
inhibited, and the tolerance to the gut microbiome and food antigens is safeguarded [46]. 
The mechanism of peripheral tolerance includes direct suppression of effector T cells by 
induction of anergy or apoptosis and conversion of T cells into Tregs [42]. 
There are many pathways to induce anergic T cells, one of them is by tolerogenic/immature 
dendritic cells, which did not reach full maturation. Therefore, antigen presentation and 
subsequent recognition by T cells is not sufficient to activate and induce proliferation of 
these cells, as these APCs do not deliver the adequate co-stimulatory signals [46]. In 
addition, Tregs can stimulate T cell anergy state through the expression of certain cytokines, 
such as Il-10 and TGF-β. Furthermore, some negative stimulatory molecules such as CTLA-
4 and PD-1/PD-L1 can also lead to T cell anergy, and some reports show that animals with 
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loss of CTLA-4 or PD-L1/PD-1 present abnormal lymphoproliferation and autoimmunity [46, 
54-57] . 
Not only immune cells can induce this anergy state, but instead, in non-small cell lung 
cancer (NSCLC), melanoma, and other types of tumours, these immune checkpoint ligands 
are highly expressed, showing that tumour cells can express these negative co-stimulatory 
ligands in order to promote their tolerization [46, 58, 59]. 
In the case of induction of apoptosis of autoreactive T cells, Fas (CD95) and Bim seem to 
have an important role for peripheral tolerance. These are involved in death pathways and 
animals deficient for both proteins have been shown to lose peripheral tolerance, with an 
increase in the number of T cells, mainly in the lymph nodes and spleen [54, 60-62]. 
In the tumour site or in peripheral tissues, T effector cells can be converted to Tregs, and, 
despite the mechanisms being still poorly understood, the presence of TGF-β and IL-2 
seems to have an impact in this conversion to a more “tolerogenic” profile [63-65]. 
Overall, Tregs have an important role in maintaining homeostasis at peripheral sites and 
this tolerance can be used by tumour cells to create an immunosuppressive 
microenvironment [43]. 
 
1.5. Immunotolerance induced by cancer cells: role of regulatory T cells 
Regulatory T cells are one subtype of CD4+ T cells originally discovered by Sakaguchi in 
1995 as a CD4+CD25+ population of lymphocytes with the ability to suppress other immune 
cells in response to self-antigens [66]. For this reason, these cells are known to be involved 
in the prevention of autoimmune diseases, as well as in controlling the inflammatory 
response, anti-tumour immunity, among others. Nevertheless, the characterisation of this 
type of T cells was ambiguous because the CD25 marker is commonly expressed in all 
activated T cells, and thus, not all CD25+CD4+ T cells may have a suppressive function or 
represent Tregs [67, 68]. 
In the 2000s, the Forkhead box P3 (FoxP3) expression by Tregs was discovered [67]. Later 
reports asserted FoxP3 as an important marker for the characterisation of Treg populations 
and established this marker as crucial for the development and immunosuppressive 
functions of this unique lineage of CD4+ T cells [46, 68]. Moreover, the development of two 
autoimmune disorders, IPEX syndrome in humans and scurfy in mice, are now associated 
with the presence of mutations in the FoxP3 gene [68, 69]. These syndromes are a result 
of the loss of Tregs, showing the importance of this transcription factor [68]. Although recent 
reports have found transient FoxP3 expression in other T cells, it is more sustained in Tregs, 
continuing to be a key marker for these cells [70, 71]. Nowadays, the combination of FoxP3+, 
CD4+ and CD25+ expression is commonly used to characterise the immunosuppressive 
Treg population [72]. 
João Augusto Freitas | MSc Oncology 
 
The origin of tumour-infiltrating regulatory T cells  
 
11 
Later, other markers were found such as PD-1, CTLA-4, the glucocorticoid-induced TNFR-
related protein (GITR), lymphocyte activation genes (LAG-3) or inducible T cell costimulator 
(ICOS), but none of them were found to be exclusive for Tregs [73]. 
Depending on the local of origin of Tregs, these can be divided into two different groups: 
thymus-derived Tregs (tTregs) or peripheral Tregs (pTregs) [74]. The former, also known 
as natural Tregs, comprise about 6-10 % of total CD4+ T cells in the peripheral blood and 
are formed in the thymus, as a result of intermediate avidity interactions between developing 
thymocytes and self-antigens-MHC complexes provided by APCs or thymic cells [46, 51, 
75, 76]. This mechanism is not yet understood but, so far, it is recognized that TCR 
signalling strength, the presence of IL-2 and TGF-b, and FoxP3 expression are crucial for 
this process [71]. Moreover, Watanabe et al. showed that the location within the thymus 
where the antigen is encountered could also be decisive for tTreg development [77]. 
In extra thymic tissues, pTregs are formed by conversion of CD4+ T cells upon non self-
antigen presentation to naïve or effector CD4+ T cells and they are important in peripheral 
tolerance [64, 68]. To date, little is known about this process but TGF-b is thought to be 
involved in upregulation of FoxP3 expression, leading to the conversion of CD4+ T cells into 
pTregs [71, 78]. Additionally, pTregs can be divided in type 1 regulatory T cells, which are 
important in local immunosuppression and organ transplantation [79] and T helper 3 (Th3), 
which are important in oral tolerance [80]. 
Despite the existence of different markers to characterise Tregs, it is still impossible to 
distinguish between pTreg and tTreg populations, due to unspecificity for Treg lineage and 
to transient expression profiles in certain cases. Therefore, a lot of work has been done to 
define new specific markers, especially at the membrane, that can distinguish these 
populations in order to evaluate if they present distinct functions and/or antigen specificities 
[81-83]. Furthermore, this knowledge will be crucial for the understanding of the mechanism 
of each subset in the context of cancer or autoimmune diseases, and, consequently, for the 
development of putative immunotherapeutic strategies to target these cells [81]. 
Recently, two markers have been considered to distinguish these two populations: Helios 
and Neuropilin-1 (NRP1). Thornton et al. described the expression of Helios, a member of 
the Ikaros transcription factor family, as being important in lymphocyte development and as 
specific marker to distinguish pTregs from tTregs, in both humans and mice [82]. According 
to this author, all CD4+CD8-FoxP3+ thymocytes express Helios and 70% of Tregs in 
peripheral lymphoid tissue are Helios+, therefore being tTregs [82]. Still, several other 
reports demonstrated that Helios was not an efficient marker to distinguish the tTreg and 
pTreg, since it was expressed in the presence of antigens, showing to be a better marker 
for activation than characterisation of the Treg lineage [84, 85]. Additionally, Szurek et al. 
compared Helioshigh and Helioslow cells against their TCR repertoire and the comparison 
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obtained indicated no differences between these populations [81]. Later, Yadav and his 
colleagues identified NRP1 protein as a new marker of tTregs [83]. In an experiment 
conducted using induced Tregs, they showed that these cells express low or undetectable 
NRP1 levels and, as a consequence, a high expression of this marker would be 
synonymous to tTregs [83]. However, Szurek et al. published contradictory results showing 
that NRP1 was not a good marker for tTregs since the TCR repertoire between NRP1low or 
NRP1high cells was very similar, meaning that both lineages were comparable [81]. For this 
reason, the use of both markers to distinguish these subsets should be used with caution, 
and other markers are still required for a complete separation of Tregs regarding their origin 
[81]. 
Despite the lack of markers to distinguish between pTregs and tTregs, and thus, the inability 
to explore Treg origin, the presence of Tregs in tumour site is of major importance, as shown 
by solid evidence from multiple reports [86, 87]. Nevertheless, the existence of tumour-
infiltrating Tregs (tiTregs) has different prognostic values, depending on the type of cancer 
[86]. In studies with patients with head and neck squamous cell carcinoma [73], breast 
cancer [88], melanoma [89] or pancreatic ductal adenocarcinoma [90], for example, the 
presence of tiTregs is associated with poor prognosis. In contrast, patients with colorectal 
adenocarcinoma [91] or follicular lymphoma [92], the presence of tiTregs is associated with 
a good prognosis. Interestingly, an explanation has emerged for some of these controversial 
results. In the case of colorectal cancer, which has a good prognosis in the presence of 
tiTregs, the inflammation provoked by certain bacteria which promotes carcinogenesis is 
suppressed by Tregs and, thus, can benefit the host [73]. 
The recruitment of Tregs and expansion at the tumour site can occur by different 
mechanisms. One of them is chemoattraction promoted by chemokines released by cancer 
or innate immune cells. Some pairs of C-C motif chemokine ligand (CCL) and C-C 
chemokine receptors (CCR), such as CCL17/CCL22-CCR4, CCL5-CCR5 or CCL20-CCR6 
and CCL28-CCR10, are involved in this recruitment [74, 93, 94]. In addition, accumulation 
of Tregs in cancer may be explained by the release of molecules, such as TGF-b, which 
promote the differentiation from effector T cells to Tregs and their proliferation [74, 95]. The 
suppressive capacity of tiTregs is higher at the tumour site than in peripheral blood, and it 
may derive from activation of Tregs after exposure to tumour antigens. Because tumour 
antigens derive from self-antigens, Tregs are preferentially activated compared to effector 
T cells [74, 96]. 
Once activated, Tregs can supress a high range of immune cells and there are several 
pathways through which Tregs can do this, namely by the release of soluble factors like 
TGF-b, IL-10, perforins and granzymes (Figure 4) [87, 97]. In addition, expression of 
immune checkpoint molecules such as CTLA-4, LAG-3 and ICOS is associated with 
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enhanced suppressive activity and promotion of tumour progression [22, 74, 97]. The 
consumption of IL-2 and the expression of CD39 and CD73, which can convert exogenous 
ATP into adenosine, act synergically to inhibit effector T cells [22, 97]. A recent study by 
Akkaya et al. has reported that antigen specific Tregs have the ability to remove the specific 
MHC-peptide complex from dendritic cells, demonstrating a new mechanism for T cell 
suppression that may also justify why some immunotherapeutic strategies do not work [98]. 
 
Figure 4.  Suppression mechanisms used by Tregs to inhibit APC and effector T cells. Reprinted from 
[99]. 
 
In summary, there is a lot of evidence supporting the importance of tolerance in tumour 
escape from the immune response. More specifically, Tregs have been identified as the 
main players in this context. A lot of work has been done to better understand the activity 
and recruitment of these cells but there is still a lot that remains to be elucidated. More 
importantly, it is necessary to understand the origin of tiTregs and their function regarding 
their lineage. Thus, the identification of good markers to distinguish these populations will 
be key for the development of new treatments against cancer in the future. 
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2. Aim 
 
It is clear that immunotolerance has a big impact in tumour progression. Tregs may be the 
main factor contributing to immune suppression in cancer, and their presence is associated, 
in some cases, with a worse prognosis. For this reason, it is important to better dissect the 
role of tiTregs, namely their origin, function, markers and recruitment to the tumour site. 
Despite the fact that some suppressive mechanisms were already identified, Treg lineages 
and their impact in tumour development are poorly understood. 
To clarify that, the main goal of this work is to determine the origin of tiTregs. We 
hypothesized that the Treg population in the tumour site may be both pTregs and tTregs 
showing the importance of both types of tolerance, peripheral and central, in tumour 
immune escape. 
Specific objectives for this work included: 
1- Assessing the presence of Tregs in the tumour site of two different mouse models: 
an inducible mouse model of colorectal cancer, the Lrig1CreERT2/+;Apcflox/+ mice and MC38-
derived subcutaneous tumours in FoxP3eGFP.DTR.Luci mice. The analysis and characterisation 
of the tumours infiltrate were performed by flow cytometry and immunohistochemistry. 
2- Determining the origin of tiTregs by comparing the TCR-b sequences between 
tumour-infiltrating Tregs and CD4+ Teff cells, using next-generation sequencing (NGS). If the 
TCR-b sequences show a match between both cell types, it indicates peripheral conversion, 
whereas if they are different, it directs to a central origin of Tregs. 
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3. Material and Methods 
 
3.1. Cell line 
The C57BL/6 mouse-derived colorectal adenocarcinoma cell line MC38 was purchased 
from Kerafast (Boston, MA, USA). Cells were grown in recommended complete medium: 
RPMI 1640 with L-Glutamine medium supplemented with 10% heat inactivated Fetal Bovine 
Serum (FBS) (both from Biowest, Nuaillé, France) and 1% Penicillin-Streptomycin 
(GIBCO®, Life Technologies, Carlsbad, CA, USA), and kept under conventional cell culture 
conditions, in a humidified atmosphere containing 5% of CO2 at 37ºC. 
When cultures reached approximately 80% of confluence, subculture was performed. For 
this purpose, the medium was removed from the flask and cells were washed with Trypsin-
EDTA solution (0.05% trypsin, 0.02% EDTA) (Sigma-Aldrich®, St. Louis, MO, USA) and left 
in the incubator until cells were detached from the flask surface. Trypsin activity was then 
blocked with FBS, present in the complete RPMI medium that was added to the cell 
suspension at this point. Cells were transferred to a Falcon tube and centrifuged at 1200 
rotations per minute (rpm) for 5 minutes (min) ((Centrifuge 5810, rotator A-4-62, (Eppendorf, 
Germany)). After discarding the supernatant, the cell pellet was resuspended in complete 
medium and seeded in new flasks/tubes. 
The cell line used in this work was tested for Mycoplasma spp. This possible contamination 
was assessed by PCR using specific primers for 16S RNA of Mollicutes (forward primer, 
GPO1: 5’- ACT CCT ACG GGA GGC AGC AGT A – 3’ and reverse primer, MGSO: 5’- TGC 
ACC ATG TGT CAC TCT GTT AAC CTC – 3’ [IDT – Integrated DNA Technologies, 
Coralville, IA, USA]). 
 
3.2. Mice 
In this dissertation, two different mouse models were used: Lrig1CreERT2/+;Apcflox/+ mice and 
FoxP3eGFP.DTR.Luci mice, kindly gifted by Prof. Robert J. Coffey (Vanderbilt University Medical 
Center, USA) and by Prof. Natalio Garbi (University of Bonn, Germany), respectively. 
All mice were housed in a specific pathogen-free environment under strictly controlled light 
cycle conditions (12 hours of light/dark), and allowed a standard rodent chow, and water ad 
libitum. 
All experiments using animals were carried out with the permission of the local animal 
ethical committee in accordance with the European Union Directive (2010/63/EU) and 
Portuguese law (DL 113/2013). The experimental protocol was approved by the ethics 
committee of the Portuguese official authority on animal welfare and experimentation 
(Direção-Geral de Alimentação e Veterinária – DGAV). 
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3.2.1. Lrig1CreERT2/+;Apcflox/+ mice 
The Lrig1CreERT2/+;Apcflox/+ mouse model, described by Powel et al., was chosen as an 
inducible model and conditional genetically engineered mouse model (GEMM) of intestinal 
tumorigenesis [100]. 
These mutant mice were generated with insertion of a tamoxifen-inducible Cre recombinase 
(CreERT2) into the translational initiation site of the endogenous Leucine-rich repeats and 
immunoglobulin-like domains 1 (Lrig1) locus and the insertion of LoxP sites flanking the 
exon 14 of the Apc gene. 
These animals were injected with 2 or 4 mg of Tamoxifen (Sigma-Aldrich®, St. Louis, MO, 
USA) diluted in corn oil (Sigma-Aldrich®, St. Louis, MO, USA) by intraperitoneal injection, 
once a day for 3 consecutive days, leading Lrig1+ progenitor cells to lose one copy of the 
Apc gene. Then, the spontaneous loss of heterozygosity of the second Apc allele results in 
a predictable pattern of neoplastic lesions, culminating in multiple, highly dysplastic tumours 
along the small and large intestine. For that reason, animals were monitored for weight, 
appearance and behaviour once a week. Additionally, after 50-70 days of tamoxifen 
induction, mice were monitored by colonoscopy every 20-30 days for signs of tumour 
formation in the distal colon. 
The euthanasia procedure, done by cervical dislocation was performed when the animal 
reached a humane endpoint due to advanced disease (100-310 days after induction, with 
tumour burden varying from mouse to mouse). 
In all experiments of our study, heterozygous mice for CreERT2 and Apcflox were used to 
guarantee the expression of Lrig1 and that the second hit in the Apc allele occurs later. 
Lrig1-WT, Lrig1CreERT2 and Apcflox allele were identified by PCR from genomic DNA of ear 
punch biopsies using the following primers: for Lrig1- WT (forward primer - 
TCTGGCTGCTCTTGCTGCTACT, reverse primer - GACTTCACGAGGCACACTCGAT ) 
for Lrig1CreERT2 (forward primer - TCATCGCATTCCTTGCAAAAGT reverse primer - 
GACTTCACGAGGCACACTCGAT and for Apc allele (forward primer-5′- 
GGCTCAGCGTTTTCCTAATG) reverse primer- 5′- GATGGGTCTGTAGTCTGGG) (IDT – 
Integrated DNA Technologies, Coralville, IA, USA). 
 
3.2.2. FoxP3eGFP.DTR.Luci mice 
The FoxP3eGFP.DTR.Luci mice are bacterial artificial chromosome (BAC) transgenic mice, 
generated by Suffner et al. [101]. In this transgenic mouse model, a construct composed of 
the cDNAs for enhanced green fluorescent protein (eGFP), human diphtheria toxin receptor 
(DTR) and luciferase gene was inserted at the start codon (ATG) in the third exon of the 
FoxP3 gene and randomly integrated into the genome of the C57BL/6 (B6) mouse. The 
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coding sequences were separated by a self-cleaving 2A peptide sequence for 
stoichiometric production of the three individual transgenic proteins.  
All experiments were performed using heterozygous animals for the transgenic construct. 
Typing was carried out by PCR from genomic DNA of ear punches biopsies using the 
following primers: DTR Forward – 5´GCCACCATGAAGCTGCTGCCG3’ and DTR Reverse 
– 5’ TCAGTGGGAATTAGTCATGCC3’ (IDT – Integrated DNA Technologies, Coralville, IA, 
USA). 
 
3.3. Animals procedures 
 
3.3.1. Subcutaneous tumour induction 
In the case of FoxP3eGFP.DTR.Luci mice, the MC38 tumour cell line was injected 
subcutaneously to induce tumour formation. 
On the injection day, cultured cells were collected from the tissue culture flask, centrifuged 
and resuspended in PBS (Fisher Scientific, Hampton, New Hampshire, EUA). Cellular 
viability was measured, in order to inject healthy cells in the animals, through dilution with 
Trypan Blue dye (Gibco®, ThermoFisher Scientific, Waltham, MA, USA). Viable cells were 
automatically counted by an TC20TM automatic cell counter (Bio-Rad, Hercules, CA, USA). 
The animals were anesthetised by isoflurane inhalation, and 1x106 MC38 cells were 
injected subcutaneously in 100 µl of saline solution. 
They were monitored every 2/3 days after the injection in terms of behaviour, weight, 
appearance and tumour size. A digital caliper (Toolland, Gavere, Belgium) was used to 
measure two perpendicular dimensions of the tumour: the longitudinal diameter (length) 
and the transverse diameter (width). Tumour volume was estimated by the modified 
ellipsoidal formula ! = #$%& , where L is the length and W is the width. 
Mice were euthanized by cervical dislocation between 20-30 days after MC38 inoculation 
or when tumour size reached 2000 mm3, the animal became moribund or tumour ulceration 
was appeared. 
 
3.3.2. Colonoscopy 
Colonoscopy was used to monitor tumour development in the Lrig1CreERT2/+;Apcflox/+ mice 
(Figure 5). 
The Mainz Coloview mini-endoscopic system [KARL STORZ, Tuttlingen, Germany] was 
used to perform colonoscopies on the mice. The animals were anesthetised before they 
received an enema with 100-150 µl of saline solution (0.9% NaCl) using a catheter. After 
the mouse expelled the faeces, colonoscopy was started inserting the endoscope with a 
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camera in the anus, applying air flow to inflate the colon and the appropriate lighting for 
proper visualization. 
After some images of the colon were captured the endoscope was removed, and the animal 
placed in its respective cage and monitored until regain of consciousness. 
 
  
Figure 5. Representative colonoscopy images from tumour development in Lrig1CreERT2/+;Apcflox/+ mice 
performed between 50 days after the injection of tamoxifen and on the day of the euthanasia. (A) a visible 
tumour showing an advanced stage of tumour development; (B) no macroscopic visualization of tumours.  
 
3.3.3. Blood collection 
To collected blood samples, cardiac puncture was performed before cervical dislocation. 
As this is an invasive approach, it was performed in an anaesthetic state using isoflurane 
inhalation. Briefly, a syringe with a 25 G needle was inserted on the animal´s side, bellow 
of the elbow until it reached the animal’s heart. The blood collected was inserted in a K3 
EDTA tube (AQUISEL®, Barcelona, Spain), which has an anticoagulant substance. 
 
3.4. Collection of single-cell suspension from different tissues 
 
3.4.1. Tumour  
Tumours collected from Lrig1CreERT2/+;Apcflox/+ mice were cut into 2-3 µm pieces and were 
then incubated with collagenase IV solution (90% RPMI 1640 with L-Glutamine medium, 
10% FBS, 1 mM CaCl2, 1 mM MgCl2 and 100 U/ml collagenase IV) in a thermoblock 
(VWRTM, Radnor, PA, USA) at 37 ºC and 600 rpm for 30 min. The volume of tumour should 
be less than 1/3 of volume of collagenase IV solution to facilitate the digestion. 
Subsequently, the sample was passed through a 70 µm cell strainer (Corning®, Sigma-
Aldrich®, St. Louis, MO, USA) and was washed until a single-cell suspension was obtained. 
Afterwards, a centrifugation step of 5 min at 1700 rpm was performed and the pellet was 
resuspended in 1 ml of FACS Buffer (PBS (1X) + 2% FBS). Cellular viability was assessed 
by the same approach as previously described (Section 3.3.1.). 
A B 
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The digestion of MC38-derived subcutaneous tumours was very similar to the approach 
performed for Lrig1CreERT2/+;Apcflox/+ tumours. Despite the samples being larger than the 
intestinal tumours, they went through two additional phases, one before the incubation of 
the thermoblock and another after this, using the gentleMACS™ Dissociators (MACS, 
Miltenyi Biotec, Germany) to facilitate the tissue digestion. Moreover, after determining the 
cellular viability, the samples were enriched to hematopoietic cells, by performing the 
positive selection of CD45+ cells using magnetic activated cell sorting CD45 Microbeads 
(MACS, Miltenyi Biotec, Germany) and LS separation columns according to the 
manufacturer´s instructions. Briefly, cells were labelled with CD45 Microbeads and the cells 
suspension passed through a LS column, which is placed in magnetic field of MACS 
separator, being the CD45+ T cells retained in the column. Later, the column was removed 
from the magnetic field and CD45+ T cells were eluted. Finally, the cellular viability was 
determined (Section 3.3.1). 
 
3.4.2. Spleen  
In order to obtain single-cell suspensions from spleens, manual disruption was performed 
to digest the organ using a syringe plunger against the tissue in a 70 µm cell strainer 
(Falcon®, Corning, Tewsbury, MA, USA). The sample was centrifugated at 1700 rpm for 5 
min at 4 ºC (Centrifuge 5810R, S-4-104 Rotor, (Eppendorf, Germany)), the supernatant was 
removed and the pellet was resuspended in 5 ml Red Blood Cell Lysis Buffer (1 volume of 
Tris hydrochloride (Tris-HCl) + 9 volumes of ammonium chloride (NH4Cl)) and incubated for 
5 min at room temperature (RT). 
Finally, the samples were re-centrifuged using the same conditions as mentioned above 
and resuspended in 1 ml of FACS Buffer. The number of viable cells was assessed as 
previously described (Section 3.3.1). 
 
3.4.3. Blood  
After blood collection, the sample was centrifuged at 1200 g for 10 min and the supernatant 
was discarded. Then, the pellet was resuspended in 5 ml Red Blood Cell Lysis Buffer and 
incubated for 5 min at RT. Later, two more centrifugations were performed for 5 min at 1700 
rpm, followed by pellet resuspension in 1ml of FACS buffer, in both centrifugations. Finally, 
viable cells were collected and assessed as previously described (Section 3.3.1). 
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3.5. Immunohistochemistry and H&E staining 
To prepare samples for haematoxylin and eosin (H&E) staining and immunohistochemistry 
analysis, tumours were collected from Lrig1CreERT2/+;Apcflox/+ mouse and each one was 
placed in a tissue processing/embedding cassette, properly identified with the identification 
of the animal and its localisation, and immersed in 10% formalin (Bio-optica, Milan, Italy). 
After 24 hours, tissue processing was performed, where cassettes and tissues were 
immersed in a sequencing of solutions: 70% ethanol, 80% ethanol, 90% ethanol, 2 
consecutive rounds in 100% ethanol, 3 rounds in Clear Rite for 1 hour each and 2 rounds 
in Paraffin for 1 hour and 20 minutes each. Lastly, tissues were embedded in paraffin wax 
for later analysis of histological sections. 
Using a microtome (Micron HM 335E), tissue sections of 4 µm were obtained and fitted in 
coated slides (Thermofisher Scientific, Waltham, MA, USA) and then they were incubated 
overnight at 37 ºC and stored at RT until perform immunohistochemistry or H&E assay. 
To perform an immunohistochemistry assay, firstly the tissue was deparaffinised through 
immersion of the slide in xylene solution (VWR, Radnor, PA,USA) in two rounds of 5 
minutes and then hydrated with 100% ethanol  for 5 min and two rounds of 5 min with 70% 
ethanol followed by incubation for 5 min under running water. 
Next, the antigen retrieval was executed by putting antigen unmasking solution retrieval 
with pH6 citrate-based buffer (Vector Labs, Burlingame, CA, USA) in slides and into a water 
vaporizer machine for approximately 35 min at 99 ºC. Afterwards, slides were left at RT to 
cool down and subsequently washed twice in 0.1% (v/v) PBS-Tween solution (PBS-T) 
(Tween 20, (Sigma-Aldrich®, St.Louis, MO, USA)) for 5 min with agitation. 
Later, the slides were incubated for 15 min with 3% hydrogen peroxide (Sigma-Aldrich®, 
St. Louis, MO, USA) in methanol (VWR, Radnor, PA, USA) to inactivate the endogenous 
peroxidases and washed in two rounds of PBS-T, as previously described. 
Tissue sections in slides were delimitated using a hydrophobic pen (Vector Labs, 
Burlingame, CA, USA) and then using the appropriate volume of Ultravision Protein block 
solution (Thermofisher Scientific, Waltham, MA, USA) to cover the whole tissue section, the 
incubation was performed for 15 min at RT. The next step was the incubation with the anti-
FoxP3 antibody, ab54015, (Abcam, Cambridge, UK), previously optimized to diluted 1:1000 
in ready to use Antibody diluent OP Quanto (Thermofisher Scientific, Waltham, MA, USA) 
in a humidified chamber for 1 hour at RT. A negative control was performed in each sample, 
in which, instead of adding primary antibody, PBS was utilized. After the slides were washed 
in PBS-T for 5 minutes, with gentle agitation to remove excess of primary antibody, they 
were incubated with secondary antibody diluted 1:100 Swine Anti-Rabbit 
Immunoglobulins/Biotin (Agilent, Santa Clara, CA, USA) for 30 min at RT. 
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A washing step with PBS-T was performed again as mentioned above and followed by 
incubation with streptavidin (Lab VisionTM Ready-To-Use Streptavidin Peroxidase, 
(Thermofisher Scientific, Waltham, MA, USA)) for 30 min at RT. 
The interaction of biotin and streptavidin was detected through the use of Dako REALTM 
Diaminobenzidine (DAB) diluted 1:20 in substrate buffer in which a brown staining was 
produced at the site of reaction. The interaction with DAB was stopped by washing slides 
under running water for 5 min when the brown colour became visible on the slide or a 
maximum of a minute. Subsequent slides were incubated in haematoxylin solution (MercK, 
Darmstadt, Germany) for one minute to stain the nucleus and, then, a wash under running 
water was done for 5 min. Slides were dehydrated with ethanol (70% of ethanol solution for 
5 min and two rounds in 100% ethanol for the same time) followed by two rounds of 
incubation of 5 min with xylene solution. Ultimately, DPX mounting medium (Sigma-
Aldrich®, St.Louis, MO, USA) was used to mount coverslip (Normax, Marinha Grande, 
Portugal) on slides.  
To analyse the tumour histology, H&E staining was performed. The slides were incubated 
twice in 100% xylene solution for 5 min followed by two rounds of immersion in 100% 
ethanol for 5 min and one cycle of incubation of 70% ethanol was performed. Subsequently, 
the slides were washed under running water for 5 min. After the slides were stained in 
haematoxylin solution to stain the nucleus for 3 min, another step of incubation under 
running wash was performed for 12 min. Thereafter, the slides were rinsed in 70% ethanol 
for 20 seconds and incubated for 1 min in eosin solution to stain the cytoplasm. Afterwards, 
the slides were dehydrated in 70% ethanol for 5 min and 2 rounds of 100% ethanol for 5 
min. An incubation of 5 min in xylene solution was performed twice and, finally, the 
coverslips were mounted on the slides by using DPX mounting medium. 
Finally, the slides from immunohistochemistry staining and H&E staining were analysed in 
optical microscope. 
 
3.6. Immunophenotyping of T cells 
The immunophenotyping protocol was performed using cell suspensions from tumours, 
spleen and/or blood. Initially, cells from the spleen, blood and Lrig1CreERT2/+;Apcflox/+ tumours 
were blocked with Fc block in 10 µg/ml for 5 min at 4 ºC, to decrease non-specific 
interactions with the antibodies of interest. Afterwards, cells were stained with an antibody 
mix composed of anti-CD3 (FITC), 1.67 μg/mL, monoclonal; anti-CD4 (PerCP), 0.4 μg/mL, 
monoclonal; anti-CD25 (PE-Cy7), 2 μg/mL, monoclonal – all from eBioscienceTM 
Thermofisher Scientific, Waltham, MA, USA – for 30 min at 4 ºC. The mix also contained a 
fixable live/dead dye, the Zombie NIRTM dye (BioLegend®, San diego,CA, USA). 
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After incubation with these antibodies, cells were fixed and permeabilized with 
FoxP3/Transcription Factor Staining Buffer Set (eBioscienceTM Thermofisher Scientific, 
Waltham, MA, USA) before incubation with anti-FoxP3 (APC), 10 μg/ml, monoclonal 
(eBioscienceTM Thermofisher Scientific, Waltham, MA, USA) for 30 min at 4 ºC. After this 
last incubation, cells were transferred to round bottom 5 ml tubes with filter caps (35 μm) 
(FALCON®, Corning Science, Tamaulipas, México) and analysed in BD FACS CANTOTM 
II cytometer (BD Biosciences, San Jose, CA, USA) or sorted in the BD FACS Aria™ II 
cytometer (BD Biosciences, San Jose, CA, USA).  
MC38-derived subcutaneous tumours were also blocked with Fc block, using the same 
conditions as referred above. Afterwards, cells were stained with a mix composed of anti-
CD4, anti-CD25 and the Zombie NIR™ dye in the same conditions as previously mentioned. 
Finally, cells were transferred to round bottom 5 ml tubes with filter caps (35 μm). 
Figure 6A presents the gating strategy used to sort the cells of interest in blood, spleen and 
Lrig1CreERT2/+;Apcflox/+ tumours. Briefly, among single cells, viable CD4+T cells were selected 
based on the lack of staining with Zombie NIR™ and the detection of CD3 and CD4 
labelling. Among these, Tregs were defined as CD25+ FoxP3+ cells whereas CD4+ Teff cells 
were considered to be FoxP3- cells. The strategy to isolate Tregs and CD4+ Teff cells from 
MC38-derived subcutaneous tumours was very similar, with exception of CD3 labelling 
(Figure 6B). 
After sorting, cells were collected in lysis buffer solution (MagMAX™ mirVana™ Total RNA 
Isolation Kit, Thermofisher Scientific, Waltham, MA, USA). 
All the data was analysed using FlowJo (V10) software (FlowJo® LLC, Ashland, OR, USA). 
 
 
 
Figure 6. Gating strategy used for flow cytometry to sort populations of interest (CD4+Teff cells and Tregs); (A) 
from Lrig1CreERT2/+;Apcflox/+ blood and tumour samples and (B) from MC38-derived subcutaneous tumour. 
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3.7. RNA extraction 
For RNA extraction from sorted cells, the MagMAX™ mirVana™ Total RNA Isolation Kit 
(Thermofisher Scientific, Waltham, MA, USA) was used. From the original protocol, two 
steps were adapted. First, as we collected sorted cells in the lysis buffer instead of directly 
resuspending a cell pellet in this buffer, the lysis buffer was diluted with FACS buffer. 
Second, the magnetic beads were dried at RT with the Eppendorf tube open during 4-6 min, 
as an alternative to shaking the beads for 2 min. 
 
3.8. RNA quantification 
After extraction, RNA was quantified using the Bioanalyzer equipment (Agilent 
Technologies, Santa Clara, CA, USA) to evaluate the quantity and quality of RNA. The 
former was obtained by RIN (RNA integrity number) that range from 1 (very fragmented) to 
10 (undamaged RNA). 
 
3.9. Sequencing of TCRb 
The RNA from sorted CD4+ Teff cell and Tregs was used to sequence the samples. The Ion 
AmpliSeq Mouse TCR Beta SR-RNA protocol (Thermofisher Scientific, Waltham, MA, USA) 
was followed, as instructed by the manufacturer. Briefly, a first step using the transcriptase 
reverse was performed, followed by amplification of the target sequences. Next, the 
amplicons were partially digested and the barcode plus the adapter were ligated to the 
amplicons. Subsequently, a quantification of the library was performed by quantitative PCR 
(qPCR), using the Ion Library TaqMan® Quantitation Kit (Thermofisher Scientific, Waltham, 
MA, USA). Finally, the template was prepared by Ion Chef and was later sequenced by Ion 
S5™ XL Sequencer. The data was analysed with the Ion Reporter™ software. Figure 7 is 
a representative TCRb repertoire from peripheral blood (positive control). 
 
Figure 7. Representative image of TCRb repertoire from peripheral blood sample without sorting. 
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3.10. Statistical analysis 
Statistical analysis of the results was performed using GraphPad Prism Software (version 
8). 
The Kruskal-Wallis test with Dunn´s multiple comparison was used to analyse the 
differences in numbers and area of lesion in each part of the intestine tissue to characterise 
the LrigCreERT2/+;Apcflox/+ mice and to evaluate the lymphocyte composition in 
Lrig1CreERT2/+;Apcflox/+ tumour applying a 95% confidence interval , with p values under 0.05 
were considered significant. 
To test differences between total productive reads between Tregs and CD4+ Teff cells from 
Lrig1CreERT2/+;Apcflox/+ blood and tumour samples, we used two-tailed Mann-Whitney test 
applying a 95% confidence interval and p value under 0.05 were considered significant. 
In subcutaneous tumours, we evaluate also the differences in term of percentages between 
CD25- FoxP3+ T cells and Tregs using also two-tailed Mann-Whitney test. A 95% 
confidence interval was applied and p value under 0.05 were considered significant. 
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4. Results 
 
4.1. Lrig1CreERT2/+;Apcflox/+ mouse model 
 
4.1.1. Characterisation of tumour formation 
The Lrig1CreERT2/+;Apcflox/+ mouse model used in this study was chosen for its ability to lose 
one copy of Apc in Lrig1+ progenitor cells after being injected with tamoxifen. As a result, 
these mice develop multiple tumours in intestinal and colonic tissues after the second hit in 
the Apc gene occurs spontaneously. The animals developed tumours along the 
gastrointestinal (GI) tract (proximal, intermediate and distal section of the small intestine, 
and the cecum plus colon). 
The average number and area of the lesions in each segment of the GI tract is showed in 
Figures 8A and B, respectively. As can be observed, most tumours sprout in the proximal 
area of the small intestine (p<0.0001, when compared to the other segments of the GI tract), 
with an average value of 4.77 tumours per animal. Moreover, tumour development was 
almost fully penetrant in this intestinal area, with only 5 out of 31 mice that did not develop 
any macroscopic lesions until euthanasia day. Seven mice developed tumours in the 
intermediate region of the small intestine, showing an average of 0.38 tumours per mouse 
in this area. In the distal area of the small intestine, tumour formation was observed in 6 
animals, with an average number of 0.9 tumours per animal. Only 12 of 31 animals 
presented lesions in the colon or cecum, resulting in an average of 0.48 tumours per animal. 
Despite the highest number of tumours being observed in the proximal region, the largest 
lesions (average area in mm2) were detected in the colon, although not statistically 
significant compared with other segments of GI (Figure 8B). Among 10 animals, the size 
(area) of tumours from the proximal segment of the small intestinal was statistical 
significantly higher than the lesions found in the distal part of the GI tract (p<0.05). 
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Figure 8. Distribution of tumours along the gastrointestinal tract (proximal, intermediate and distal part of the 
small intestinal and cecum plus colon) in Lrig1CreERT2/+;Apcflox/+ mice. (A) number of tumours detected in each 
segment of the GI tract. Each dot represents a different animal (n=31); (B) area of each lesion, in mm2, per 
region of the intestine/colon, in a total of 10 mice. Each dot represents a lesion. Kruskal-Wallis test with Dunn´s 
multiple comparison was performed for statistical comparisons between groups. All possible comparisons 
between each part of GI was performed in terms of tumour number and size. Only statistically significant 
differences were identified with * (p<0.05) or **** (p<0.0001). Error bar is for standard deviation. 
 
4.1.2. Immunophenotyping of spleen and tumour samples - protocol 
optimisation 
Cells from the spleen were used to optimise the immunophenotyping protocol for detection 
and isolation of tumour-infiltrating lymphocytes. This organ was chosen due to the large 
number of lymphocytes present and the percentage of immune subsets available are 
already documented. Several different conditions were tested, such as the incubation time 
for fixation and permeabilization of cells, concentration of antibodies, temperature for 
antibody incubation and number of washes. 
After we were able to undoubtedly isolate each population of interest in the spleen (Figure 
9A) – including the isolation of the CD4+ T cells and Tregs populations – we proceed to the 
characterisation of these populations in the tumour samples. Figure 9B shows the gating 
strategy used for analysis of the different populations of cells. Although not as clear as 
previously observed in the case of the spleen, it was possible to distinguish the cells of 
interest for this project. 
Curiously, in the tumour samples, a population of cells that we did not detect before became 
apparent – the CD4+FoxP3+CD25- T cell population. 
A B 
Pr
ox
im
al
Int
erm
ed
iat
e
Di
sta
l
Ce
cu
m+
Co
lon
0
10
20
30
Tu
m
ou
r n
um
be
r
✱
✱
✱
Pr
ox
im
al
Int
e m
ed
iat
e
Dis
tal
Ce
um
+C
olo
n
0
10
20
30
Tu
m
ou
r n
um
be
r
✱
✱
✱
Pr
ox
im
al
Int
erm
ed
iat
e
Dis
tal
Ce
cu
m+
Co
lon
0
10
20
30
Tu
m
ou
r n
um
be
r
✱
✱
✱
Pr
ox
im
al
Int
erm
ed
iat
e
Dis
tal
Ce
cu
m+
Co
lon
0
10
20
30
Tu
m
ou
r n
um
be
r
✱
✱
✱
Pr
ox
im
al
Int
erm
ed
iat
e
Dis
tal
Ce
cu
m+
Co
lon
0
10
20
30
Tu
m
ou
r n
um
be
r
✱
✱
Pr
ox
im
al
Int
erm
ed
iat
e
Dis
tal
Ce
cu
m+
Co
lon
0
10
20
30
Tu
m
ou
r n
um
be
r
✱
✱
Pr
ox
im
al
Int
erm
ed
iat
e
Dis
tal
Ce
cu
m+
Co
lon
0
10
20
30
Tu
m
ou
r n
um
be
r
✱
✱
Pr
ox
im
al
Int
erm
ed
iat
e
Dis
tal
Ce
cu
m+
Co
lon
0
10
20
30
Tu
m
ou
r n
um
be
r
✱
✱
Pr
ox
im
al
Int
erm
ed
iat
e
Dis
tal
Ce
cu
m+
Co
lon
0
10
20
30
Tu
m
ou
r n
um
be
r
Pr
ox
im
al
Int
r
ed
iat
e
Dis
tal
Ce
cu
m+
Co
lon
0
10
20
30
Tu
m
ou
r n
um
be
r
✱
✱
Pr
ox
im
al
Int
rm
ed
iat
e
Dis
tal
Ce
cu
m+
Co
lon
0
10
20
0
Tu
m
ou
r n
um
be
r
✱
✱
Pr
ox
im
al
Int
rm
ed
iat
e
Dis
tal
Ce
cu
m+
Co
lon
0
10
20
30
Tu
m
ou
r n
um
be
r
✱
✱
Pr
ox
im
al
Int
rm
ed
iat
e
Dis
tal
Ce
cu
m+
Co
lon
0
10
20
30
Tu
m
ou
r n
um
be
r
✱
Pr
ox
im
al
Int
erm
ed
iat
e
Di
sta
l
Ce
cu
m 
+C
olo
n
0
10
20
30
 T
um
ou
r s
iz
e 
(m
m
2 )
?
Pr
ox
im
al
Int
erm
ed
iat
e
Dis
tal
Ce
cu
m+
Co
lon
0
10
20
30
Tu
m
ou
r n
um
be
r
✱
✱
✱
João Augusto Freitas | MSc Oncology 
 
The origin of tumour-infiltrating regulatory T cells  
 
29 
The herein established protocol (see Materials and Methods section 3.6) was then followed 
for the sorting of CD4+ Teff and Tregs cells from Lrig1CreERT2/+;Apcflox/+ tumours in the next 
section. 
 
 
 
Figure 9. Gating strategy used to isolate the populations of interest after optimising the immunophenotyping 
protocol. (A) Flow cytometry analysis of cell suspensions from the spleen and (B) Flow cytometry analysis from 
Lrig1CreERT2/+;Apcflox/+ tumour samples. 
 
4.1.3. Immune composition at the tumour site 
After the immunophenotyping optimisation was concluded, we assessed the immune 
composition in tumour samples from Lrig1CreERT2/+;Apcflox/+ mice. 
For that, we used the CD3, CD4, FoxP3, CD25 labelling and zombie (viability dye) to 
observe the percentage of CD8+ T cells (CD3+CD4-), CD4+ T cells (CD3+CD4+), Tregs 
(CD3+CD4+ FoxP3+CD25+) and CD25-FoxP3+ T cells (CD3+CD4+CD25-FoxP3+) among all 
viable cells (Figure 10). 
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Figure 10. Analysis of tumour-infiltrating lymphocytes by flow cytometry. Among viable cells, CD8+ T cells is 
selected by expression of CD3 and lack expression of CD4, while CD4+ T cells are gated by staining of CD3 
and CD4. Among CD4+ T cells, the gating for Treg cells is based on the expression of FoxP3 and CD25. The 
gating for CD25-FoxP3+ T cells was based in the absence of expression of CD25 and strong staining of FoxP3.  
 
Figure 11 shows the composition of immune cells from tumours samples of 
LrigCreERT2/+;Apcflox/+ mice. Each dot represents the analysis of tumour-infiltrating 
lymphocytes, in percentage of total number of cells, from a pool of tumours from one animal. 
As can be observed, the percentage of CD4+ T cells ranged between 2.36 to 7.17% of total 
viable cells, with an average value of 4.73%; on the other hand, the percentage of CD8+ T 
cells varied between 1.29 and 11.9%, with an average of 4.89%. Using a Kruskal-Wallis 
test, this difference in the average percentage of CD4+ T versus CD8+ T cells was not 
statistically significant. The average amount of Treg cells in the tumours samples was of 
1%, while the percentage of CD25-FoxP3+ T cells was about 1.6%. Although being slightly 
higher, the percentage of CD25-FoxP3+ T cells was also not statistical significantly different 
from the percentage of Tregs.  
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Figure 11. Immune composition of tumour samples from LrigCreERT2/+;Apcflox/+ mice. Each dot represents the 
analysis of a pool of tumours taken from one animal. The columns show the mean +/- standard deviation of the 
percentage of CD4+ T cells, Tregs, CD25- FoxP3+ T cells and CD8+ T cells in the total number of viable cells 
(n=12). Kruskal-Wallis test with Dunn´s multiple comparisons were performed, and no significant differences 
were observed between CD4+ T vs. CD8+ T cells and Tregs vs. CD25-FoxP3+ T cells pairs (p>0.05). 
 
To confirm the presence of Treg cells and their localisation at the tumour site, histological 
analysis of tumours was also performed (Figures 12 and 13). Figure 12 shows the 
histological analysis of a colonic dysplastic lesion from Lrig1CreERT2/+;Apcflox/+ mouse stained 
with haematoxylin and eosin, where a small amount of tumour-infiltrating immune cells was 
observed, and most of them at the stroma site. 
The presence of few FoxP3+ cells intratumorally was observed by histological analysis when 
we performed a staining with anti-FoxP3 antibody (Figure 13). Moreover, a high density 
staining in normal tissue adjacent to the tumour could be observed. 
In summary, the flow cytometry and histological analysis showed that Tregs were present 
in tumours. 
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Figure 12. Representative haematoxylin and eosin staining in a colonic tumour sample from 
Lrig1CreERT2/+;Apcflox/+ mouse. Scale bar, 100 µm. 
 
  
Figure 13. Representative FoxP3 staining (brown) in a tumour sample from small intestine from the 
Lrig1CreERT2/+;Apcflox/+ mouse model. Scale bar, 100 µm. The zoom-in image was taken at an 4x amplification. 
N- Normal tiisue adjacent to the tumour site. T- tumour site. 
 
4.1.4. RNA extraction from CD4+ Teff cells and Tregs sorted from tumour and 
blood cell suspensions 
In order to accomplish the main goal of this dissertation, is pivotal to obtain a pure population 
of CD4+ Teff cells and Tregs, in order to avoid contamination in the TCRb clonotypic 
repertoire. For that reason, these populations were isolated from tumour samples by cell 
sorting in flow cytometry. 
The gating strategy used to sort the populations of interest is based on Figure 6A (both for 
blood and tumour samples). Briefly, among viable cells, CD4+ T cells were selected based 
on expression of CD3 and CD4 cell surface markers. Afterwards, from that population, CD4+ 
Teff cells were established as the ones with lack of FoxP3 expression, whereas Tregs were 
N T
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sorted from the FoxP3+CD25+ population. Figure 14 shows a representative simplified 
gating strategy used to sort the populations of interest. 
 
 
Figure 14. Representative gating strategy (simplified) to sort Tregs and CD4+ Teff cells from 
Lrig1CreERT2/+;Apcflox/+ tumour and blood samples. Among CD4+ T cells, CD4+ Teff cells were sorted based on 
lack expression of FoxP3 marker whereas Tregs were selected based on expression of CD25 and FoxP3. 
 
Sorted cells were collected in Lysis Buffer (MagMAX™ mirVana™ Total RNA Isolation Kit) 
and RNA extraction was performed immediately after, in order to preserve the RNA quality. 
RNA quantification and quality analysis were determined using the 2100 Bionalyzer 
Instrument. Tables 2 and 3 summarise the number of CD4+ Teffs and Tregs sorted cells from 
tumours and blood samples, respectively, as well as the RNA yield and RIN, to quantify the 
RNA integrity (from 1 (very fragmented) to 10 (undamaged RNA)) obtained for each sample. 
As can be observed, the amount of Treg cells fluctuates among the different samples, as 
well as the number of CD4+ Teff cells, showing the heterogeneity of quantity and percentage 
of tumour-infiltrating immune cells between animals. It is also possible to observe that RIN 
was very low in all samples. Moreover, the RNA quantification was not proportional with the 
number of cells previously sorted. 
 
Table 2. Number of sorted cells for each substet of CD4+ T cell population from Lrig1CreERT2/+;Apcflox/+ 
tumours samples. The RNA yield and correspondent RIN value of each population is also presented. 
Animal ID Subset of CD4+ T 
cells 
Number of 
sorted cells 
RNA yield 
(pg/µl) 
RIN 
218FD CD4+Teff cells 11863 90 2 
Tregs 6270 48 1 
180FDETD CD4+Teff cells 14609 291 2.5 
Tregs 2088 199 2.3 
272FDE CD4+Teff cells 7282 208 2.5 
Tregs 13251 610 2.5 
264FD CD4+Teff cells 24219 1090 2.5 
Tregs 84254 2424 2.3 
299TD CD4+Teff cells 12729 74 2.5 
Tregs 4255 67 1.4 
229FDTD CD4+T eff cells 16410 169 2.5 
Tregs 4345 122 2.4 
357FDTD CD4+Teff cells 16832 154 2.5 
Tregs 30889 35 1.5 
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Table 3. Number of sorted cells for each substet of CD4+ T cell population from Lrig1CreERT2/+;Apcflox/+ blood 
samples. The RNA yield and correspondent RIN value of each population is also presented. 
Animal ID Subset of CD4+ 
T cells 
Number of 
sorted cells 
RNA yield 
(pg/µl) 
RIN 
272 FDE CD4+Teff cells 21690 616 2.5 
Tregs 1663 71 1.2 
299TD CD4+Teff cells 94333 884 1.1 
Tregs 7924 34 2 
229FDTD CD4+Teff cells 327755 820 2.5 
Tregs 14259 69 2.6 
357FDTD CD4+Teff cells 101623 631 2.5 
Tregs 5943 31 2 
 
 
4.1.5. Sequencing of TCRb clonotypes of CD4+ Teff cells and Tregs from 
tumour and blood samples 
The best samples were selected for TCRb sequencing in terms of RNA yield and quality. 
Also, the possibility of having blood samples from the same animal was considered, as this 
parameter could provide extra information about the conversion site of circulating Tregs and 
tiTregs. 
For this reason, samples from the animals 272FDE, 229FDTD and 264FD were selected. 
In Figures 15 A and B are a representative classification of the obtained reads, where they 
are classified as productive reads, rescued productive reads, unproductive reads and off-
target reads. This result allowed us to acknowledge if the frequency of total productive 
reads, constituted by productive reads plus rescued productive reads, was big enough to 
represent the population of tumour-infiltrating lymphocytes. In all samples, the percentage 
of total productive reads in the overall number of reads ranged between 0.9 and 5.9%, 
exposing the inefficient representation of lymphocyte population in our tumour and blood 
samples. As can be observed in Figure 16, the number of total productive reads was very 
low. Despite this, the total number of productive reads was not statistically significant among 
the sorted populations (Tregs and CD4+ Teff cells), meaning that they received a comparable 
coverage between them (Figure 16). Then, we analysed the TCRb repertoire of CD4+Teff 
cells and Tregs from blood and tumour samples (Figure 17). Each dot in Figure 17 
represents the presence of at least one clonotype for that specific CDR3 length and V 
segment. The diversity of the TCR clonotypes was achieved by the distribution of dots in 
the CDR3 length and the V region and by colour dots (dark green dots represent more 
TCRb clonotypes with the same V-CDR3 length, whereas white dots represent less TCRb 
clonotypes with the same V-CDR3 length). The frequency of V-CDR3 length is symbolized 
by the size of dots, with bigger dots representing more frequent clones. 
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The number of clones sequenced from both populations of interest ranged from 10 to 102. 
Then, we observed the diversity and frequency of TCR clonotypes in each sample. Due to 
the low number of clonotypes, some samples show a small diversity of TCRb clonotypes 
and not distributed in all V regions (Figure 17B and 17D). In contrast, others show a huge 
diversity of TCRb clonotypes not only in specific V regions with the same CDR3 length 
(green dots) but also distributed in more segments in variable region (Figure 17A and 17C). 
In most of the cases, the frequency of clones was bigger in TCRb clonotypes with the same 
CDR3 length (green dots) instead of a single TCR clonotype (white dots). 
 
 
Figure 15. Representative image of reads classification after sequencing of TCRb of CD4+ Teff and Tregs 
samples from Lrig1CreERT2/+;Apcflox/+ tumours. The productive and rescued productive reads are the ones 
analyzed by the sequencer. (A) Read classification in Treg sample from a pool of tumour; (B) Read classification 
in CD4+ Teff cells from a pool of tumours formed. 
 
 
 
Figure 16. Number of total productive reads obtained after sequencing of TCRb sequences from 
Lrig1CreERT2/+;Apcflox/+ tumour and blood samples sorted lymphocytes. Each dot represents the number of total 
productive reads for each sample of CD4+Teff cells and Tregs sequenced (n=5). Two tailed Mann-Whitney test 
was used for statistical analyses. No significant differences were observed between total productive reads from 
both populations, (p>0.05). Error bar is for standard deviation. 
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Figure 17. 
Representative 
distribution of TCRb 
clonotypes present in the 
sorted populations from 
Lrig1CreERT2/+;Apcflox/+ 
tumour and blood 
samples. 
Representation of TCRb 
clonotypes present in 
(A)/(B) Tregs/ CD4+ Teff 
cells population in tumour 
and (C)/(D) Tregs/ CD4+ 
Teff cells in blood from 
272FDE mouse; The 
sequences are distributed 
by their CDR3 length, and 
each dot represents the 
presence of clones for that 
specific V segment and 
CDR3 length. The 
diversity of clones in each 
dot is represented by 
colour (from white to dark 
green) and the frequency 
by size (bigger dots 
represent the presence of 
more frequent V-CDR3 
sequences). 
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4.1.6. Comparison between the TCRb sequences of CD4+ Teffs with Tregs in 
tumour vs blood samples 
After sequencing the TCRb repertoire from CD4+ Teff cells and Tregs, we next compared the 
sequences from both populations to infer about the origin of tiTregs. By comparing the 
CDR3 region in the TCRb sequence between the populations of interest, we observed that 
a small proportion of the sequences overlap between CD4+ Teff cells and Tregs collected 
from tumour samples (Figure 18). Only in tumour samples from 264FDTD and 272FDE 
animals were observed the presence of 3 TCRb clonotypes that shared the same TCRb 
sequence between CD4+ Teffs and Tregs, showing that most of Treg clonotypes present at 
the tumour site have a central origin. 
Moreover, we also compared the TCRb sequences from these populations in blood versus 
tumour samples (Figure 19). In blood samples from 229FDTD mouse, there were 7 TCRb 
sequences shared between Tregs and CD4+ Teff cells (Figure 19A). Figure 19B shows one 
TCRb clonotype shared by tiTregs with Tregs in blood and another TCRb clonotype shared 
by Tregs in blood and both CD4+ Teff populations, in blood and in tumour. 
In addition, 3 TCRb sequences overlapped between the TCRb repertoire of CD4+ Teff 
population with TCRb repertoire of Tregs population from blood samples and other 3 TCRb 
sequences were shared in Tregs and CD4+ Teff populations from tumour. Regarding these 
3 TCRb clonotypes, the ranking of frequency of them in tiTreg population were 13rd ,16th 
and 53th. 
 
 
 
 
          
 
Figure 18. Comparision of TCRb sequences between tumour-infiltrating CD4+ Teff cells and Tregs collected from 
Lrig1CreERT2/+;Apcflox/+ mice. The overlapp region between circles present the number of TCRb sequences shared 
by both populations. 
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Figure 19. Comparison of the TCRb sequences between CD4+ Teff cells and Tregs from blood and tumour 
samples collected from Lrig1CreERT2/+;Apcflox/+ mice. (A) Comparison between CD4+Teff cells and Tregs in tumour 
and blood samples from 229FDTD mouse; (B) Comparison between CD4+Teff cells and Tregs in tumour and 
blood samples from 272FDE mouse. Blue and yellow circles indicate the number of CD4+ Teff cells and Tregs 
clonotypes sorted from tumours, respectively. Green and red circles show the number of TCRb clonotypes from 
CD4+Teff and Tregs cells sorted from the blood, respectively. 
 
 
4.2. FoxP3eGFP.DTR.Luci mouse model  
 
4.2.1. Evaluation of tumour growth kinetics 
Due to the poor number of total productive reads obtained from the neoplastic and blood 
samples collected from Lrig1CreERT2/+;Apcflox/+ mice, we decided to sort cells from tumours of 
a different mouse model, the FoxP3eGFP.DTR.Luci mice. In this model, all FoxP3+ cells express 
the enhanced green fluorescence protein (eGFP), which allow their identification and 
sorting without the need to fix or permeabilize them. 
Six animals (4 females and 2 males) were subcutaneously inoculated with 1x106 MC38 cells 
(in 100 µl of saline solution) for tumour development. Tumour growth kinetics is presented 
in Figure 20 showing that only three out of the six mice developed a visible tumour. 
Moreover, the tumour growth rate was very different among animals, with the 7FE mouse 
presenting the highest tumour growth rate, whereas the 9TD mouse had the lowest. 
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Figure 20. Tumour growth kinetics in FoxP3eGFP.DTR.Luci mice after subcutaneous inoculation with MC38 
cells. One million cells were inoculated subcutaneously and the tumour growth was monitored every 2-3 
days . Tumour volume is presented in mm3. The cross symbol represents the day of euthanasia. 
 
4.2.2. Immune cells composition at the tumour site 
The animals that developed a visible tumour were euthanized between 20 and 30 days after 
inoculation or when tumour reached 2000 mm3. Subsequently, tumours were collected 
followed by digestion and immunophenotyping by flow cytometry to characterise the 
immune composition of the MC38-derived subcutaneous neoplastic lesions. For that, Tregs 
and CD25-FoxP3+ T cells were analysed accordingly to the gating strategy presented in 
Figure 21, and the percentage of these populations among all viable cells was quantified 
(Figure 22). 
 
 
Figure 21. Gating strategy used for the analysis of tumour-infiltrating lymphocytes in FoxP3eGFP.DTR.Luci mice by 
flow cytometry. Among viable cells, CD4+ cells were gated by staining of CD4. Among these, the gating for Treg 
cells was performed in the FoxP3+ and CD25+ population. CD25-FoxP3+ T cells were also selected, based in 
absence of CD25 expression and strong staining for FoxP3. 
The results show that Treg cells are present in these tumours in a proportion of about 0.2% 
of all viable cells, although having some variability among tumour samples (Figure 22). 
Interestingly, the presence of a population of CD25- FoxP3+ T was also detected, comprising 
around 0.1% of the total number of viable cells. No significant differences were observed in 
the percentage of both populations among viable cells. 
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Figure 22. Immune composition of MC38-derived tumours collected from FoxP3eGFP.DTR.Luci animals 
analysed by flow-cytometry. Each dot represents the percentage of immune cells quantified using a 
tumour sample from a different animal. Two-tailed Mann-Whitney test was used for statistical analyse. No 
significant differences between groups (p>0.05) were observed. Error bars stands for standard deviation. 
 
4.2.3. RNA extraction from CD4+ Teff cells and Tregs sorted from MC38-
derived tumours 
The number of sorted CD4+Teff cells and Tregs is shown in Table 4. The number of Tregs 
sorted seemed to be proportional with tumour size on euthanasia day (Figure 20), whereas 
the number of CD4+ Teff cells was more homogenous among samples, despite their 
differences in terms of size. After sorting these populations, total cell RNA was extracted 
and quantified both for yield and quality (integrity) in the 2100 Bioanalyzer Instrument (Table 
4). 
 
Table 4. Numbers of sorted cells for each substet of CD4+ T cell population from MC38-derived subcutanous 
tumours. The RNA yield and correspondent RIN to each population is also presented. (N/A-non aplicable) 
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• 672 • 160 •  678 •  38 •  395 •  22 
• RIN • 3.9 • 3.9 •  2.5 •  2.5 • 2.3 •  N/A 
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4.2.4. Sequencing of TCRb clonotypes of CD4+ Teff cells and Treg cells and 
comparison of their TCRb repertoire 
 
The same sequencing approach as described before for the Lrig1CreERT2/+;Apcflox/+ mouse 
model samples was performed. Although, due to technical issues, only one (7FE) out of the 
three samples collected from the FoxP3eGFP.DTR.luci mice was possible to sequence. From the 
other 2 samples, no reads were detected for the Treg population and therefore we were not 
able to use the data from CD4+ Teff sequencing to achieve our aim. The classification of 
reads obtained for the 7FE sample is presented in Figure 23. As can be observed, we were 
able to obtain a total of 63% of productive reads for CD4+ Teff cells and 53% for Tregs, plus 
2.7 and 3% of rescued reads, respectively. The diversity and frequency of TCRb clonotypes 
present in each sample is illustrated in Figure 24. 
Figures 24A and 24B show the presence of 243 TCRb clonotypes for the Tregs population 
and 1016 TCRb clonotypes for the CD4+ Teff population, respectively. The distribution of 
TCRb clonotypes in both populations indicated a huge diversity based on the number of 
dots presented in a wide range of variable region and the presence of green dots in certain 
CDR3 length. Comparing the distribution of both populations, the TCRb repertoire of CD4+ 
Teff cells appears to be similar with TCRb repertoire of Tregs. None of Figures 24A and 24B 
indicate a single TCRb clonotype with a high frequency (big white dots) whereas TCRb 
clonotypes with the same CDR3 length have a high V-CDR3 frequency. 
 
 
 
 
Figure 23. Read classification of sequencing in Tregs and CD4+ Teff population from MC38-derived 
subcutaneous tumour. The productive and rescued productive reads are the ones analyzed by the sequencer. 
(A) Read classification in Treg sample from MC38-derived subcutaneous tumours. (B) Reads classification of 
CD4+ Teff cells from MC38-derived subcutaneous tumour. 
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Figure 24. Distribution of TCRb clonotypes present in the sorted populations from the MC38-derived 
subcutaneous tumours. (A) TCRb clonotypes distribution of Tregs and; (B) CD4+ Teff cells. The sequences are 
distributed by their CDR3 length, and each dot represents the presence of clones for that specific V segment 
and CDR3 length. The diversity of clones in each dot is represented by colour (from white to dark green) and 
the frequency by size (bigger dots represent the presence of more frequent V-CDR3 sequences). 
 
Finally, we analysed the sequencing data and compared the CDR3 of the TCRb sequence 
between both populations to understand the origin of Tregs sorted from MC38-derived 
tumours (Figure 25). We observed that 102 TCRb clonotypes are shared between these 
two populations, suggesting that, based on the CDR3 region from the TCRb, there are 102 
Treg clones peripherally converted from CD4+ Teff cells.  
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Figure 25. Comparision of TCRb sequences between tumour-infiltrating CD4+ Teff cells and Tregs from a MC38-
derived subcutaneous tumour developed in FoxP3eGFP.DTR.Luci mice. The overlapp region between circles 
present the number of TCR sequences shared by both populations. 
 
 
4.3. Comparison between TCRb repertoire of tumour-infiltrating CD4+ Teff 
cells and Tregs in different animals 
Finally, we assessed if tumour-infiltrating CD4+ Teff or tiTregs could share the same TCRb 
clonotypes in different animals, by comparing all samples amongst each other (from both 
Lrig1CreERT2/+;Apcflox/+ and FoxP3eGFP.DTR.Luci mice). The results from this comparison are 
represented in Figures 26A and 26B, for CD4+ Teff cells and Tregs, respectively. Tumour-
infiltrating CD4+ Teff cells did not show any overlap between different animals in terms of 
CDR3 region of TCRb, whereas in the case of the Treg clonotypes, only one was shared 
between tiTregs from the animals 264FD and 272FDE. Despite this TCRb clonotype shared 
by these Tregs populations, this T cell clone had a low frequency in both populations, less 
than 0.1 %. This data expose that the response/recruitment of cells to the tumour site was 
realized by diverse T cell clonotypes in different animals. 
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Figure 26. Comparison of the TCRb sequences between CD4+ Teff cells and Tregs from tumour samples 
collected from both Lrig1CreERT2/+;Apcflox/+ and FoxP3eGFP.Luci.DTR mice. Comparison between (A) CD4+ Teff and 
(B) Treg populations gathered from different animals. Red and green circles show the number of TCRb 
clonotypes from 264FD and 7FE mice, respectively. Yellow and blue circles present the number of TCRb 
clonotypes identified in 229FDTD and 272FDE tumour samples. 
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5. Discussion 
Immunotherapy with immune checkpoint blockers has changed the cancer treatment 
landscape over the last years. However, despite remarkable clinical results, about 80% of 
patients do not respond to this type of therapy [22]. This suggests the existence of 
alternative mechanisms of escape to cancer immune response. 
The ability of Tregs to infiltrate neoplastic lesions has already been proven, contributing to 
the increased tolerance from the immune system towards tumour cells in the majority of 
cases [86, 87]. Moreover, in most cancer types, the presence of Tregs at the tumour site is 
associated with a worse prognosis for patients’ overall survival [86]. Despite their presence 
being well documented, little is known about the origin of tiTregs – they can be derived from 
the thymus (central origin) or from the peripheral conversion of CD4+ T cells (peripheral 
origin). Only two markers, NRP1 and Helios, have been proposed to distinguish Tregs 
regarding their origin [81]. However, their use for Treg differentiation has been questionable 
with some articles showing that Helios is a marker of cell activation in presence of antigens 
and that the TCR repertoire of NRP1high and NRP1low was similar, suggesting that they share 
the same lineage [81, 85]. 
Taking this into consideration, to date, there is no specific marker to distinguish these Treg 
lineages. For this reason, the main goal of this dissertation is to elucidate the origin of 
tiTregs. 
To achieve this aim, an inducible and conditional mouse model of intestinal/colonic 
tumorigenesis, the Lrig1CreERT2/+;Apcflox/+, was used [100]. This model represents more 
faithfully the natural occurrence of tumours in the intestinal/colon tissue by loss of one Apc 
allele in Lrig1+ cells. 
We started the work by characterising the mouse model. To do so, the location of tumours, 
number and size were registered. Despite the development of tumours along the small 
intestine and colon as previously documented, the number and typical localization of 
tumours were altered compared to what was reported in the original publication by Powel 
et al., who kindly gifted us the mice [100]. The authors reported an average around 40 
tumours per animal, being most of them in the jejune region. However, the maximum 
number of tumours detected by us was of 33, with an average of 6.5 per animal. Moreover, 
the location of the GI tract with the highest number of tumours detected was in the proximal 
part of small intestine (duodenum), with an average of 4.7 tumours per mouse. One possible 
explanation for this phenomenon can be related with the mice microbiome, as it will be 
different among distinct animal facilities. Some reports have shown that differences in 
microbiome lead to different growth kinetics and number of tumours, especially in the 
intestinal tissue, where the presence of certain species of bacteria could favour the process 
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of carcinogenesis [102-104]. Another explanation can be related to the process of mice 
rederivation in our animal facility, since the animals lost their C57BL/6 background to sv129, 
which might altered the susceptibility of these animals to develop tumours [105]. 
Having characterised the mouse model, we next analysed the collected tumours to confirm 
the presence of tumour-infiltrating Tregs. For that, the immune composition of a pool of 
tumours (representing one sample) collected from different Lrig1CreERT2/+;Apcflox/+ mice was 
analysed by flow cytometry. Cells were stained with anti-CD3, anti-CD4, anti-CD25 and 
anti-FoxP3 antibodies to distinguish between CD8+ T, CD4+ T and Treg populations, and 
may understand if the percentages of these cells in the immune infiltrate of these samples 
is homogenous between mice and to evaluate the presence of tiTregs. Interestingly, a 
population of CD25-FoxP3+ T cells that we did not expect to observe was also detected in 
some of these samples, and in some cases, in a higher percentage than the Treg 
population. The origin or function of this population is not well understood so far, but some 
authors have claimed that it constitutes a reservoir for Treg generation that can upregulate 
CD25  expression upon homeostatic expansion  and therefore, activated Tregs [106]. Other 
reports described that this population can lose the FoxP3 expression and become T helper 
cells, or that CD25-FoxP3+ T cells turn out to be immunosuppressive in aged mice [107-
109]. Two possible explanations for the presence of this type of inactivated Tregs are 
correlated with a) the suppression of Tregs activity by tumour influence or b) the recruitment 
of cells that have not interacted with an antigen yet and will be converted into Tregs after 
expressing CD25. However, these two hypotheses are speculative with little support given 
by the literature so far [65, 106, 108]. 
The analysis of the immune composition showed no statistically significant differences 
between pairs of CD4+ T cells and CD8+ T cells plus Tregs and CD25-FoxP3+ T cells. This 
data indicates that these tumours have a similar proportion of the CD8+ T cells and CD4+ T 
cell populations (<5%), and the same is true for the other analysed populations (~1%). 
Wang et al. showed that, in human cancers, there is a better prognosis in overall survival 
and progress free survival rates in triple-negative breast cancer patients that had a ratio of 
CD4/CD8 above 1 [110]. Additionally, a study by Shah and co-workers have determined 
that a CD4/CD8 ratio below 1 and the presence of high infiltration of Tregs are associated 
with worst prognosis in squamous cell carcinoma of the cervix [111]. Despite these 
observations, in tumours from Lrig1CreERT2/+;Apcflox/+ mice we detected a ratio of CD4/CD8 
around 1, and they are not considered to be highly infiltrated by Tregs (only 1% of all viable 
cells in tumour). Thus, our results could not be correlated with the previous reports. 
The presence of tiTregs in the neoplastic lesions was also confirmed by 
immunohistochemistry. Even though it was possible to observe a high density of staining in 
the lesion periphery (normal tissue adjacent to the tumour tissue), small amounts of tiTregs 
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in intratumoural site were detected. This could be responsible for the formation of a 
favourable tumour microenvironment, leading to the suppression of the immune response 
in the peripheric region of tumour.  
Due to the relative low amount of immune infiltration in these tumours and the fact that they 
have relatively low dimensions, the number of cells that we could sort from these samples 
was very low (Table 2 – Results Section). Therefore, the quantity of RNA was predictable 
to be also lower. Moreover, due to the necessity to fix and permeabilize cells for the 
intracellular staining of FoxP3, the RNA integrity was compromised [112, 113]. Also, the 
process of tissue digestion and immunophenotyping lead to cell stress and may result in 
the activation of endogenous RNases, contributing for less quantity and quality of RNA and 
even cell death. 
Because these issues, the samples used for TCRb sequencing were not ideal, although we 
have chosen the ones with the best scores in terms of RNA quantity and integrity. To assess 
if our sequencing data was representative of the whole sample, the amount of the total 
productive reads was analysed. Unfortunately, the number obtained was very low, as 
somehow expected due to the fixation step – not only it affects RNA integrity, as it can affect 
the amplification step needed for sequencing [113]. From our experience, a minimum of 
20% of total productive reads are necessary to have a good representation of all sequences 
in the sample (unpublished data). For this reason, the results obtained from this sequencing 
do not totally represent the diversity of TCRb clonotypes present in tumour and blood 
samples from Lrig1CreERT2/+;Apcflox/+ mice. Regardless, the number of productive reads from 
both CD4+ Teff and Tregs populations was not significantly different and thus, we assume 
that the sequencing coverage for both populations was similar, being possible to compare 
them. 
After preliminary analysis of the sequenced number of reads, we evaluated the frequency 
and diversity of TCRb clonotypes from CD4+ Teff cells and Tregs present in both samples 
(blood and tumour). Due to the low number of reads sequenced, some samples had low 
number of TCRb clonotypes detected and the T cell clonotypes had preferentially the same 
CDR3 length and V segment than a similar distribution in all segments of V region. Both 
tumour-infiltrating Tregs and CD4+ Teff cells from 229FDTD mouse are an example of low 
quantity of TCRb clonotypes, which had 10 and 11 TCRb clonotypes, respectively. At the 
tumour site, we expected to observe a high frequency of some clonotypes, indicating a 
specific response to locally expressed antigens that would be represented by bigger and 
white dots (Figure 17 from results section). However, most dots with higher frequency of V-
CDR3 are composed by many clonotypes, which represent the sum of all T cell clonotypes 
with the same CDR3 length and specific V segment. But if we want to evaluate the specific 
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tumour response, we need to focus more in the amino acid sequence and their structure 
because different TCRb clonotypes can form the same protein. 
We next compared the TCRb sequences obtained from CD4+ Teff cells versus Tregs to 
achieve the proposed goal of this dissertation, which is to understand the origin of tiTregs. 
The results from that comparison clearly show that most of tiTreg clonotypes did not share 
the same CDR3 region of TCRb sequences from CD4+ Teff cells. Therefore, we can suggest 
that the majority of Treg clonotypes present at the tumour site have a central origin, which 
indicates that central tolerance plays a crucial role in tumour development. Perhaps this 
result could be explained by the expression of self-antigens by tumour cells, since they were 
transformed from normal cells, although we could not rule out the hypothesis of other 
mechanisms of transport of tumour-derived neoantigens to the thymus [52]. However, we 
need to be careful with these results because the sequencing was not fully representative 
of both populations in tumour sample, based on the reads classification regarding low 
quantity and quality of RNA. 
Regarding peripheral Tregs, an additional question remains in our mind that is if this 
conversion happens at the tumour site and is stimulated by cancer cells, or if it occurs in 
other locations caused by a peripheral tolerance and not related with cancer disease. To 
answer this question, we compared the populations of interest (CD4+ Teff cells and Tregs) in 
tumour versus blood. We did not observe any overlap between the TCRb repertoire present 
in these two samples from 229FD mouse. The data obtained with the samples collected 
from the 272FDE mice show one TCRb clonotype of tiTregs shared with circulating Tregs 
and another TCRb clonotype that is shared by Tregs in blood and CD4+ Teff from both 
samples (blood and tumour). Additionally, in the same samples from 272FDE mouse, 6 
Treg clonotypes had the same TCRb sequence of CD4+ Teff clones, meaning that they were 
converted from these cells. Interestingly, 3 TCRb clonotypes were shared between Tregs 
and CD4+Teff population from the blood, so they are probably originated by a process of 
peripheral tolerance without being related with the tumour, whereas the other 3 tiTreg 
clonotypes shared with the CD4+ Teff cells from the tumour probable result from the local 
conversion of these cells. The local conversion of Treg cells in neoplastic lesions could be 
explained by the presence of tumour-related neoantigens and by expression some 
molecules such as TGF-b, which may trigger this process [114]. 
To surpass the technical limitations of this initial study regarding the necessity for fixation 
and permeabilization of cells and consequently loss of RNA integrity, we decided to test 
another animal model to determine the origin of tiTreg, the FoxP3eGFP.DTR.Luci mice. This 
mouse is a BAC transgenic model in which a construct composed by eGFP, DTR and 
luciferase genes was inserted in the third exon of the FoxP3 gene and randomly integrated 
João Augusto Freitas | MSc Oncology 
 
The origin of tumour-infiltrating regulatory T cells  
 
49 
into the genome [101]. As a result, ~90% of FoxP3+ cells from these mice are eGFP positive 
and can be detected by flow cytometry without the need for antibody labelling. For tumour 
development, the colorectal adenocarcinoma-derived cell line (MC38) was subcutaneously 
injected, as these animals do not have an inducible system to development intestinal/colon 
tumours as the Lrig1CreERT2/+;Apcflox/+ mice. From the 6 mice initial injected with MC38 cells, 
only 3 developed a visible tumour. Previous work from our group in using MC38 cells for 
subcutaneous inoculations in mice had shown that the immune system can recognise these 
cells as non-self in some cases, due to the characteristic alterations of a cell line, 
contributing to its elimination (unpublished data). This could also be related with low cell 
viability at the time of injection or a technical difficulty in the subcutaneous injection. 
The animals were euthanized between 20 and 30 days after inoculation or when tumour 
reached 2000 mm3. Afterwards, each tumour was collected and analysed for its immune 
composition. Herein, we only evaluated the presence of Tregs and CD25-FoxP3+ T cells 
and did not account for the CD4+ T cell population. The reason for this is because the eGFP 
from FoxP3+ cells has its emission in the same wavelength of FITC, which is the 
fluorochrome conjugated with the anti-CD3 antibody available in our lab, and so it could not 
be used. As the CD4 marker is not exclusive of CD4+ T cells, since dendritic cells also 
express this protein, we decide to not include them in our evaluation [115]. When comparing 
the populations of Tregs versus CD25- FoxP3+ T cells in these tumours, the former appears 
to be at higher levels, despite this difference being not statistically significant. A higher 
number of samples is needed to understand if this phenomenon is real and to compare this 
difference with tumour size on euthanasia day or tumour growth rate. 
Due to the small percentage of tiTregs, the number of Tregs that we were able to sort was 
very low. However, a positive correlation between the number of Tregs and tumour volume 
was detected. This can occur because having a higher tumour mass will lead to a higher 
number of cells being present, including Tregs, or due to the creation of an 
immunosuppression microenvironment by Tregs that would increase tumour growth rate. 
After analyses of the tumour-infiltrating lymphocytes and their sorting, RNA extraction and 
TCRb sequencing was performed. Although we have used all samples gathered for these 
sequencing step (3 Treg samples and 3 CD4+ Teff cells collected from 3 MC38-derived 
subcutaneous tumours), 2 RNA samples from sorted Tregs were not sequenced because 
the sequencer did not recognise their barcodes. The protocol was performed twice, with a 
change in the barcode in the second attempt, but with the same result. The small number 
of cells and the low quality of RNA could be the reason for this issue. Therefore, we only 
analysed the pair of samples from one tumour (7FE). 
The percentage of total productive reads obtained from the MC38-derived tumours was 
significantly higher (56-66%) when compared to what was obtained from the samples 
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collected from Lrig1CreERT2/+;Apcflox/+ mice, validating the influence of the 
fixation/permeabilization method in this process. With these values we are confident that 
the obtained data is representative of the tumour immune composition. The results obtained 
from sequencing confirms this idea, with a bigger distribution and higher number of TCRb 
clonotypes being gathered. Despite the absence of TCRb clonotypes with high frequency 
that could be reactive for a specific antigen, there are some clonotypes showing an 
intermediate level of frequency, indicating some clonal expansion in response to some local 
antigens. 
Finally, to understand the origin of tiTregs in this mouse model, we compared the TCRb 
sequences obtained from CD4+ Teff cells and Tregs populations. A similar result to the one 
presented before was achieved, with the majority of Tregs (141 out of 243 clonotypes) 
having unique TCRb sequences and therefore being considered tTregs, reinforcing the role 
of central tolerance in tumour development [116]. Nevertheless, the percentage of pTregs 
clonotypes in this mouse model, about 40% of total of tiTreg clonotypes, is higher when 
compared to the results obtained from the Lrig1CreERT2/+;Apcflox/+ mice. In the literature, there 
are at least two studies using tumour cell lines as a model of tumour development in mice 
that described the presence of Tregs conversion from CD4+ T cells in tumour site but also 
in draining lymph node and spleen [117, 118]. 
We also compared the TCRb sequences between all the different animals used in this work, 
to understand if there is any sequence that overlaps among the same subset of cells. Only 
one TCRb clonotype was shared by two Treg populations from two Lrig1CreERT2/+;Apcflox/+ 
mice, but at a very low frequency in both cases and thus, we cannot assume that this TCRb 
clonotype that is shared by both animals is tumour specific. 
Regardless the results obtained from these TCRb sequence comparisons, there are some 
limiting parameters that must be considered. First, our TCRb repertoire is not totally 
representative of the whole repertoire of CD4+ Teff cells and Tregs present in the 
Lrig1CreERT2/+;Apcflox/+ tumour samples. Moreover, we only sequenced the CDR3 region of 
the TCRb, which is the most diverse region of this protein chain, but there is the possibility 
to occur punctual mutations in other regions of the TCRb that we do not detect using this 
analysis. Besides, we have to take into account that the TCR is a heterodimer receptor and 
most of them are also composed by another chain, the TCRa, which also has a CDR3 
region. Therefore, the number of clonotypes of CD4+ Teff and Tregs that share the same 
TCRb detected by sequencing can be inflated comparing with the real number of pTregs in 
tumour site. Despite these limitations, a recent publication by Ahmadzadeh et al. described 
similar results to those observed in this work in a variety of human cancers in terms of origin 
of tiTregs. They compared the TCRb sequences of CD8-FoxP3+ T with CD8-FoxP3- T cells 
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and showed that a minority of clonotypes are shared between these populations, but 
contrary to our findings, they detected a high frequency of overlapping TCRb clonotypes in 
same subsets of CD4+ T cells from blood versus tumours [116]. 
In summary, and despite important limitations of the study so far, in our models we were 
able to observe the presence of tiTregs, being the majority of them likely of central origin, 
which suggests that central tolerance is important in cancer development. However, in the 
subcutaneous tumour model we observe a big percentage of clonotypes to be formed in 
periphery showing that peripheral tolerance is also important to tumour progression. 
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6. Conclusion and Futures Perspectives 
In this study, we proposed to achieve two aims: identify the presence of tumour-infiltrating 
Tregs from Lrig1CreERT2/+;Apcflox/+ tumours and MC38-derived subcutaneous tumours from 
FoxP3eGFP.DTR.Luci mice, and determine the origin of tumour-infiltrating Tregs based on the 
TCRb repertoire of Tregs and CD4+ Teff cells from these two different tumour models. In the 
Lrig1CreERT2/+;Apcflox/+ tumours and the MC38-derived subcutaneous tumours, Tregs were 
present in tumour. The results of this work also indicate that the majority of tiTreg clonotypes 
do not share their TCRb sequences with CD4+ Teff. clonotypes. Therefore, we can infer that 
tiTeg clonotypes have mostly a central origin, evidencing the important role of central 
tolerance in tumour development. Although in MC38 derived subcutaneous tumour has a 
high fraction of Treg clonotypes that had a peripheral origin evidencing the crucial role of 
peripheral tolerance in this tumour progression. Despite the major proportion of tiTregs 
being tTregs, we also demonstrated that some Treg clonotypes are locally converted, 
perhaps by tumour influence, through the comparison of TCRb sequences between CD4+ 
Teff cells and Tregs in blood vs tumour samples.  
Nonetheless, this study has some limitations such as the low number of samples, small 
number of tiTregs collected and low quality of RNA. 
To reduce these limitations, MC38 will be subcutaneously inoculated in a higher number of 
FoxP3eGFP.DTR.Luci animals to increase the significance of the gathered data so far. 
Simultaneously, the Lrig1CreERT2/+;Apcflox/+ mouse model will be crossed with 
FoxP3eGFP.DTR.Luci mice to generate an inducible system of intestinal/colonic tumour 
development where all FoxP3+ cells are labelled and can be easily isolated without the need 
for further processing. Also, we would like to sequence the TCRb repertoire of CD25-FoxP3+ 
T cells to understand if it is more similar to the TCRb repertoire of Tregs or CD4+ Teff cells.  
Moreover, in both tumour models, tiTregs appear to have some biological plasticity by 
presence of thymus-derived Tregs, peripheral Tregs and an inactive population of Tregs, 
CD25- FoxP3+ T population. 
Overall, the majority of frequency of tTreg clonotypes in tiTregs and the presence of pTregs 
represent a new view about the origin of Tregs in murine tumours, with results obtained in 
two different models of cancer development. 
It remains to be established which types of antigens (tumour derived or self-antigens) 
contribute to the recruitment of these cells to the tumour site. Moreover, the function of each 
lineage of tiTregs in cancer immune tolerance continue unknown. The discovery of antigen 
specificity, function and origin of tiTregs may become a useful addition to our understanding 
of the relationship between cancer and the immune system, and help overcoming some of 
the limitations of current immunotherapy strategies.
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